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INTRODUCTION 
 
1.1 Ischemic Stroke and Neuroprotection 
Ischemic stroke encompasses 87% of all strokes in the United States and is the fourth most 
common cause of death in the country (Go et al., 2013). It is also the leading cause of long-term 
disability in adults (Go et al., 2013). By 2030, an additional 3.4 million people above 18 years will have 
had a stroke, and the prevalence of stroke survivors is projected to increase (Writing Group et al., 2016).  
During an ischemic stroke, a plaque or clot in a blood vessel results in loss of oxygen and 
glucose to the areas of the brain the vessel normally supplies causing neuronal excitotoxicity 
characterized by excessive glutamate release and hyperstimulation of NMDA receptors (Murphy et al., 
1989). Once the plaque or clot has been removed or dissolved, re-introduction of oxygen promotes a 
second wave of reactive oxygen species (ROS) generation (Young et al., 2004).  
Several clinical trials have used antioxidants and free radical scavengers as a means to decrease 
the morbidity and mortality associated with ischemic stroke (Margaill et al., 2005) with only modest 
improvement. One of the reasons for the limited success of these studies is that treatments in animal 
models are often administered at a predetermined time before or immediately after controlled ischemic 
onset. Stroke, however, is spontaneous and unforeseen, often meaning that patients do not reach a 
hospital quickly enough or within tested time windows for treatment. For example, less than 3% of adult 
patients qualify for receiving tissue plasminogen activator (tPA), a clot-buster and only FDA-approved 
drug for the treatment of ischemic stroke (often given in conjunction with antioxidant treatment in 
animals), because it must be administered intravenously within 4.5 hours of stroke onset (Powers et al., 
2018).  
 
		2	
Modeling Neuroprotection: Ischemic Preconditioning 
While prolonged ischemia is damaging to neurons, strong experimental evidence suggests that 
transient ischemic attack (TIA) prior to a more severe ischemic event can be neuroprotective (Kitagawa 
et al., 1990; Gidday, 2006). This phenomenon, “ischemic preconditioning”, can be elicited by a number 
of subtoxic stressors in addition to ischemia (Gidday, 2006) and has become a valuable paradigm for 
studying endogenous adaptive pathways in animal and cell culture models. 
Over the past 25 years, many in vivo and in vitro models of PC have been developed, revealing 
specific windows in which protection is maximal. Early PC is elicited mainly by post-translational 
modifications that recede within hours after stress, providing a very narrow window of protection. 
Classical PC evokes new protein synthesis and lasts for days to weeks in in vivo models (Stetler et al., 
2009; Stetler et al., 2014). We are most interested in the latter form of PC, as it provides a more pliable 
window in which to develop therapeutics that target the underlying adaptive pathways following an 
ischemic event.  
Models of cerebral preconditioning share key features including: new protein synthesis, 
induction of heat shock proteins, activation of mitochondrial KATP channels, and spatially and 
temporally limited activation of caspases (McLaughlin et al., 2003; Gidday, 2006). We have 
increasingly come to appreciate that signaling pathways commonly associated with apoptosis and cell 
death can also be triggered during non-lethal, preconditioning events (McLaughlin et al., 2003; Brown et 
al., 2010). 
Our working model of preconditioning suggests that ROS function as spatially- and temporally-
controlled signals, and while we have identified a variety of redox-sensitive molecules that contribute to 
protection, there remain gaps in our understanding of the roles these molecules have on essential cellular 
processes including protein and organelle degradation.  
		3	
HSP70 Is Necessary, But Not Sufficient for Preconditioning 
 Heat shock proteins (HSPs) constitute a highly conserved and functionally interactive network of 
chaperone proteins. While some HSPs are constitutively expressed, others are inducible in response to 
chemical, environmental and physiological stressors. Collectively, HSPs work to disaggregate, refold, 
and re-nature misfolded proteins in order to avoid otherwise fatal consequences. As such, many 
knockout models of heat shock proteins, the HSP transcription factor, HSF1, and HSP co-chaperones 
often exhibit severe abnormalities in their cardiovascular, reproductive and nervous systems, decreased 
growth rates and overall body size and increased aging phenotypes, all of which are associated with 
early mortality (Dickey et al., 2008; Hashimoto-Torii et al., 2014; Kim et al., 2013; Min et al., 2008; 
Wacker et al., 2009). 
 HSP70 is a cytosolic, stress-inducible chaperone that binds to multiple co-chaperones to form a 
protein triage complex. The function of this complex in either degrading or refolding client proteins 
depends on the assembly of co-chaperones. The “pro-folding” complex requires the recruitment of HIP 
and HOP with HSP70-HSP40 (Hohfeld et al., 2001). The “pro-degradation” complex requires the 
recruitment of BAG1 and CHIP with the HSP70-HSP40 complex, where CHIP ubiquitinates HSP70 
client proteins for proteasomal degradation (Hohfeld et al., 2001). Given the essential functions of 
HSP70 in proteostasis and longevity, many groups have sought to overexpress HSP70 in models of 
acute and chronic stress, protein dysfunction, neurodegeneration, and aging, acquiring mixed results.  
In models of heat stress, nitric oxide stress, and ataxia, HSP70 overexpression improves viability 
and is protective (Bellmann et al., 1996; Mosser et al., 2000; Cummings et al., 2001). However, chronic 
overexpression of HSP70 is deleterious, inhibiting normal development and reducing viability in 
Drosophila (Krebs and Feder, 1997). Additionally, in mouse models of chronic heart failure and atrial 
fibrillation, which is closely associated with ischemic stroke (Wolf et al., 1991; Adelborg et al., 2017), 
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HSP70 overexpression is not protective (Bernardo et al., 2015). In regards to preconditioning, where 
low-level stress evokes subsequent protection, HSP70 expression is necessary but not sufficient for 
neuroprotection. Only 50% of preconditioned neurons are spared in response to lethal stress despite the 
fact that all preconditioned neurons express HSP70 (McLaughlin et al., 2003). Taken together, these 
models reveal that HSP70 expression has acute protective functions, but is insufficient in long-term 
maintenance of the cellular milieu under chronic stress. This suggests that other proteins or pathways 
may be a limiting factor for maintaining protection. Given the central role of bioenergetic and redox 
signaling in stroke pathology, we hypothesized that mitochondria play a critical and underappreciated 
role in both preconditioning protection and chaperone biology.  
 
1.2 Mitochondrial Function and Dysfunction 
Redox and Energetic Homeostasis In the Central Nervous System 
Eukaryotic cells rely on mitochondria for efficient generation of energy through the Krebs cycle 
and the electron transport chain (ETC). Indeed, eukaryotes contain an average of one billion ATP 
molecules, which turn over approximately three times per minute (Kornberg, 1989). The central nervous 
system (CNS) relies heavily on aerobic respiration for ATP production. The brain utilizes over 20% of 
total oxygen respired, as well as 0.3-0.8 µmol of glucose per gram of weight per minute (µmol/g/min) 
(Erecinska and Silver, 1989), producing approximately 25-32 µmol/g/min of ATP. Notably, nearly 50% 
of this pool is required to maintain cellular ion homeostasis alone (Erecinska and Silver, 1989), thus 
underscoring the necessity for efficient ATP production by active mitochondria.  
While production of energy-rich ATP by aerobic respiration is adaptive, it also produces free 
oxygen-and nitrogen-radicals (Halliwell and Gutteridge, 1989). Not surprisingly, mitochondria produce 
the majority of ROS within neurons and approximately 3% of oxygen used for respiration captures 
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electrons inefficiently resulting in the generation of superoxide anions (Halliwell and Gutteridge, 1989). 
Given the elevated metabolic demand in neurons, maintaining redox homeostasis is crucial. ROS can 
modify protein structures and disrupt protein-protein interactions, oxidize lipids and alter membrane 
integrity, and damage DNA to disrupt normal protein synthesis (Halliwell and Gutteridge, 1989). 
Indeed, elevated ROS, decreased antioxidants, protein oxidation and lipid peroxidation are shared 
pathological features among neurological disorders (Faucheux et al., 2003; Chen et al., 2007; Hauser 
and Hastings, 2013; Rotblat et al., 2014; Dixit et al., 2017).  
Mitochondrial morphology and intracellular localization are also dependent on metabolic 
demand (Mishra et al., 2015). Mitochondria are densely packed in dendrites and axon terminals, areas 
concentrated in ATP-dependent enzymes (Pysh and Khan, 1972; Chen and Chan, 2006). To meet such 
demands, neurons continuously undergo biogenesis, fusion, and fission of mitochondria. Indeed, 
alterations in mitochondrial quality control pathways are also associated with a host of neurological 
diseases (Chen and Chan, 2006; Detmer and Chan, 2007; Chan, 2012). 
 
Discovery of Parkin and the Role of Mitochondria in Neurodegeneration 
Much of what we now understand about mitochondrial quality control comes from seminal 
research on Parkinson’s disease (PD), an age-related neurodegenerative disease characterized by loss of 
dopaminergic neurons in the substantia nigra pars compacta (SNpc). The resulting changes in 
dopaminergic tone within the basal ganglia cause hallmark symptoms of PD including cognitive decline, 
akinesia, bradykinesia and tremor.  Approximately 10% of PD patients have inherited mutations in 
genes including: SNCA, LRRK2, PARK2, PARK7, and PINK1; however, the vast majority of PD is 
sporadic in nature, with no known family history (Klein and Westenberger, 2012).  
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Parkinson’s is the second most prevalent neurodegenerative disease in the world affecting 
approximately 9,000,000 patients (Dorsey et al., 2007). Risk factors for sporadic PD include age, sex 
(males have a 1.5 time greater likelihood of developing PD), exposure to pesticides and fungicides, and 
contact with other environmental toxins (Gorell et al., 1997; Gorell et al., 1998; Van Den Eeden et al., 
2003; Taylor et al., 2007). Individuals who have suffered concussive brain injury, most notably from 
participating in football, hockey, boxing and mixed-martial art combat, have a higher incidence of PD 
and PD-like symptoms (Gardner et al., 2015; Pearce et al., 2015; Mez et al., 2017).  
The selective vulnerability of SNpc neurons to PD-induced degeneration has been linked to 
unique intrinsic properties of affected dopaminergic cells as well as circuit-specific factors such as 
requirements in firing activity, afferent neurochemical input and other regional specific features of the 
SNpc (Brichta and Greengard, 2014; Surmeier et al., 2017). One particularly appealing hypothesis first 
put forth by Jim Surmeier in 2010, incorporates aspects of these cell and circuit specific changes. This 
model features a critical role for the pacemaking properties of L-type calcium channels, whereby 
mitochondrial buffering of calcium entry through these channels increases mitochondrial oxidant 
production (Surmeier et al., 2010; Surmeier et al., 2011). The unique expression and activation of these 
channels may, therefore, place SNpc calcium buffering systems in peril. This hypothesis is also 
consistent with an important primary role for mitochondrial failure in mediating Parkinson’s pathology 
(Ahlqvist et al., 1975).  
Prior to widespread genetic analysis, the earliest and most reliable models of Parkinson’s disease 
were developed by the labs of Flint Beal, Bill Langston and Tim Greenamyre using peripheral and 
central administration of pesticides, herbicides, drugs of abuse, and other agents (Betarbet et al., 2002; 
Schlossmacher et al., 2002; Beal and Lang, 2006). While compounds that induced PD-like degeneration 
and motor symptoms were structurally unique, they shared the underlying biochemical property of 
		7	
blocking aerobic respiration (Tipton and Singer, 1993). Taken together with data from patient fibroblasts 
and imaging, these groundbreaking studies supported a central role of mitochondrial number, 
bioenergetic function, integrity and signaling in disease pathology (see reviews (Ding and Yin, 2012; 
Moon and Paek, 2015; Kang et al., 2016; Wang et al., 2016)). While our research focuses on acute 
injury, the molecules identified in PD research that regulate mitochondrial function also play critical 
roles during ischemic stress.  
Each neuron must generate, repair, and replace hundreds to thousands of biologically active 
mitochondria in order to supply sufficient ATP and calcium buffering capacity to ensure cell viability 
(Erecinska and Silver, 1989; Chang and Reynolds, 2006; Chan, 2012; Golpich et al., 2017). Therefore, it 
is not difficult to envision why the demands of constant de novo mitochondrial biogenesis are 
overwhelming, compelling mitochondria to be able to combine resources via fission and fusion or to 
isolate functional mitochondria from those that need to be recycled via autophagic processes 
(mitophagy). 
Mitofusin 1 (Mfn1) and Mitofusin 2 (Mfn2) assist in the fusion of the outer mitochondrial 
membrane (OMM), while Optic Atrophy 1 (Opa1) permits fusion of inner mitochondrial membranes 
(IMMs) (Chen and Chan, 2009). The fusion of mitochondrial membranes between organelles promotes 
ionic buffering and sharing of energetic resources. Indeed, stress-induced hyperfusion of mitochondria is 
a highly effective way for neurons to promote cell survival under acute stress, whereas under relaxed 
conditions cells are able to segregate damaged mitochondria (Chen and Chan, 2009). Hyperfusion 
occurs within minutes to hours after acute stress resulting in a highly interconnected mitochondrial 
network that enhances communication with the endoplasmic reticulum (van der Bliek, 2009). Fusion 
also allows diffusion of matrix content among mitochondria, diluting accumulated mitochondrial DNA 
mutations and oxidized proteins (Archer, 2013).  
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Mitochondrial fission reactions are regulated by Drp1, mitochondrial fission factor (Mff), and 
mitochondrial fission 1 protein (Fis1). These proteins are key in proper mitochondrial maintenance as 
they can affect the size, shape, and distribution of these organelles (Reddy et al., 2011). Cytosolic Drp1 
translocates to the OMM and assembles with Fis1 and Mff, where it uses GTP hydrolysis to constrict the 
membranes of mitochondria until scission (Mears et al., 2011).  
Cortical neuronal mitochondria have been the most widely studied primary neuronal culture 
system for mitochondrial dynamics. Mitochondria have equal fusion-fission and fission-fusion cycle 
rates of 0.023 cycles per mitochondrion per minute, or roughly one cycle completed for a single 
mitochondrion every 43 minutes (Cagalinec et al., 2013). In models of proteotoxicity in which mutant 
Huntington or Tau are overexpressed, mitochondrial fusion rates decrease, and mitochondria become 
shortened (Cagalinec et al., 2013). This is reversible by overexpression of the mitochondrial motility 
protein Miro (Cagalinec et al., 2013). While fusion rates depend on mitochondrial motility, fission rates 
depend on mitochondrial length. In cortical neurons, mitochondria will undergo fission more frequently 
when mitochondrial length exceeds 4 µm (Cagalinec et al., 2013). This constant cycling of 
mitochondrial fission and fusion is tightly regulated and subject to changes in the cellular proteome. 
Within the last decade, the role of autophagy – the controlled process of intracellular “self-
eating” – has been shown to play a critical and previously unappreciated role in neurodegeneration. 
During autophagy, signaling molecules called autophagy-related proteins (Atgs) initiate recruitment and 
formation of lipid bilayer vesicles (autophagosomes) that engulf targeted intracellular organelles and 
upon fusion with lysosomes, result in component degradation. Both neurons and glia undergo baseline 
autophagy essential for cell homeostasis (Cherra and Chu, 2008; Chen and Chan, 2009). Therefore, 
perturbations in autophagic proteins can promote aberrant death that is most profound in CNS (Hara et 
al., 2006; Komatsu et al., 2006). Defects in mitophagy, in particular, have been linked to PD as animals 
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with inherited mutations in PD genes have altered mitochondrial dynamics, cellular respiration, 
mitochondrial fission, fusion and mitophagy (Santos and Cardoso, 2012).  
 
Parkin and PINK1 Interact to Regulate Mitophagy 
The selective degradation of mitochondria is a multi-tiered system that can be triggered by single 
events or combination of stressors. Two distinct steps facilitate mitophagy: the priming of autophagic 
proteins and the selection of mitochondria for recycling (Ding et al., 2010; Egan et al., 2011; Greene et 
al., 2012; Itakura et al., 2012).  
The E3-ubiquitin ligase Parkin works closely with PTEN-induced putative kinase 1 (PINK1) to 
control mitochondrial degradation via autophagy (mitophagy). PINK1 is a serine-threonine kinase that is 
constitutively synthesized and imported to all mitochondria, but cleaved from healthy mitochondria by 
inner-membrane proteases (Greene et al., 2012). In mitochondria that fail to maintain membrane 
potential, PINK1 accumulates on the OMM, where its catalytic kinase domain is exposed and able to 
phosphorylate OMM proteins as a signal for Parkin-mediated ubiquitination (Narendra et al., 2010; 
Lazarou et al., 2013). PINK1 can also phosphorylate the linker region of Parkin itself, facilitating the 
mitochondrial translocation of this E3 ligase (Kim et al., 2008). Mutations in PINK1 and Parkin have 
been found in patients with a subtype of early onset familial Parkinson’s disease. 
While disruption of PINK1 or Parkin results in mild cellular dysfunction, such models fail to 
capture the acute vulnerability to stress or pathological features of diseases like PD (Goldberg et al., 
2003; Perez and Palmiter, 2005; Gispert et al., 2009).  These data suggest that there are aspects of 
systems- or circuit- level functions that compensate for both PINK1 and Parkin, and that more studies 
are needed to identify other proteins that can be leveraged to more closely mimic the conserved 
pathological features of aging and disease.  
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The proteins that promote engulfment, dynamic changes in mitochondrial number and function, 
and compensation of the dopaminergic circuit that results in decades-long decline and motor 
manifestation of disease require a great deal more of study. For example, Nix proteins expressed on the 
OMM are a physical tether between mitochondrial lipid membranes and engulfing autophagosomes 
speckled with LC3 and GABARAP (Ding et al., 2010; Novak et al., 2010). This engulfment and the 
processes that precede it can occur in the absence of mitochondrial depolarization, which is often 
depicted as the common trigger of mitophagy. Moreover, in highly metabolic tissues, mitophagy can 
proceed in the absence of PINK1, suggesting that mitophagy is tissue- and context-dependent 
(McWilliams et al., 2018). Indeed, any number of cues such as signaling via the outer membrane kinase 
Ulk1 (Itakura et al., 2012; Lazarou et al., 2015), as well as the cytosolic chaperones HSP90 and Cdc37 
(Weihofen et al., 2008; Joo et al., 2011) and the Nix-like protein Bnip3 (Lee et al., 2011), and triggers of 
the mitochondrial unfolded response (Jin and Youle, 2013) can all promote mitochondrial fission and 
Parkin recruitment.  
We have shown that a structurally similar E3-ligase, C-terminal of HSC70-Interacting Protein 
(CHIP) is induced by acute neurologic stress and localizes to mitochondria. Yet, the molecular cues that 
promote CHIP translocation to mitochondria remain to be identified (Palubinsky et al., 2015). Post-
mortem brain tissue from patients with a history of transient ischemic attack or ischemic stroke exhibit 
increased CHIP expression (Stankowski et al., 2011). Likewise, in vitro models of ischemia and heat 
shock promote CHIP expression and localization to mitochondria (Palubinsky et al., 2015). Acute stress 
induced by environmental toxins or bioenergetic dysfunction also increases the mitochondrial retention 
of full length PINK1 whereas total Parkin expression remains unchanged (Lee et al., 2015). Our data 
supports a model whereby CHIP, like Parkin, is recruited to mitochondria during acute stress, possibly 
through PINK1 stabilization and kinase activity. 
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Parkin Facilitates Mitophagy via Specific Structural Domains 
The specific structural elements of Parkin that contribute to mitochondrial translocation suggest 
that the RING1 domain is a critical modulator of relocalization. Overexpression of RING1 mutants fail 
to rescue the mitochondrial morphological changes observed in KO animals, indicating that the RING1 
domain is necessary (Rose et al., 2011). While the ubiquitin-like (UBL) domain is mutated in some 
patients with familial PD, Parkin does not require the UBL domain or the linker region to localize to 
mitochondria. Both the regulatory RING0 domain and the complete carboxy-terminal RING 
configuration of Parkin are also required for both mitochondrial translocation and subsequent 
mitochondrial degradation by mitophagy (Geisler et al., 2010).  
In Drosophila, Parkin translocation is dependent on phosphorylation of residues S65, T175 and 
T217, but phosphorylation at these sites is not sufficient (Narendra et al., 2010; Kane et al., 2014). These 
data suggest that RING1 and UBL domain phosphorylation are critical regulators of Parkin 
translocation. PINK1 also phosphorylates Ser65 on ubiquitin molecules (pS65-Ub) ligated to proteins on 
the OMM. Phospho-ubiquitin then binds to Parkin’s RING1 domain, inducing a conformational change 
that allows PINK1-mediated phosphorylation of Ser65 in the UBL domain of Parkin and increased E3 
ligase activity (Kane et al., 2014; Kazlauskaite et al., 2014; Koyano et al., 2014; Nguyen et al., 2016; 
Aguirre et al., 2017).  
Despite our increased understanding of PINK1-Parkin activity, many in vitro and Drosophila 
models of null or mutated PINK1 do not exhibit stress-induced Parkin translocation to failing 
mitochondria (Song et al., 2013). Much like Parkin KO animal models, mice deficient in PINK1 also fail 
to exhibit an overt behavioral phenotype or PD pathology (Kitada et al., 2009). PINK1 deficient animal 
models share more in common with Parkin-null animals than any other E3 ligase mutants or knockouts 
(Gispert et al., 2009). Given the lack of any overt phenotype, it is perhaps not surprising that Parkin 
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deletion does not alter baseline mitochondrial morphology in mice. Indeed, mitophagy can proceed 
unfettered in even Drp1 KO (Burman et al., 2017) and PINK1 KO animals (McWilliams et al., 2018). In 
studies by Kageyama and colleages, mitochondrial ubiquitination and localization of the autophagy 
adaptor protein, p62, occurred independently of Parkin (Kageyama et al., 2014).  
Taken together, we have yet to develop a full understanding of the events that cause 
mitochondria to be engulfed and how endogenous signals like energetics and ROS combine with fusion 
and fission proteins to promote or halt mitophagy. We hypothesize that local, subcellular cues are 
essential to determining neuronal fate, and that under conditions of extreme ROS formation or energetic 
stress there are redundant opportunities for mitochondria to be recycled via mitophagy.  
 
1.3 E3-ligases in Neurological Disease 
Conservation of ubiquitination as a critical regulator of protein function from yeast to humans 
underscores the importance of this post-translational modification for eukaryotic life. Over the past two 
decades, ubiquitin has been linked to apoptosis, facilitating protein-protein interactions, promoting DNA 
transcription and cell repair (Grabbe et al., 2011; Hammond-Martel et al., 2012; Husnjak and Dikic, 
2012; Zhao et al., 2014).  
During the ubiquitination process, E1 enzymes activate ubiquitin via an ATP-dependent reaction, 
forming a thioester with ubiquitin’s C-terminus. The activated ubiquitin is then transferred to a cysteine 
residue of an E2 ubiquitin conjugating enzyme. E3 ligases then carry out the final step in the 
ubiquitination cascade, catalyzing the transfer of ubiquitin from the E2 enzyme to a lysine residue of the 
substrate in a covalent manner (Reviewed by (Metzger et al., 2012)).  
Three classes of E3 ligases facilitate this ubiquitin transfer by different mechanisms and are 
distinguished by their unique structural features. They are: the RING, the HECT, and the ring-between-
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ring (RBR) E3 ligase proteins. RING family proteins catalyze the transfer of ubiquitin directly from an 
E2 enzyme to the substrate, whereas the HECT and RBR families facilitate the transfer of ubiquitin via a 
two-step trans-thioesterfication reaction (Metzger et al., 2012).  
 
Parkin Is a Redox-Sensitive RING Finger Domain E3 Ligase 
Parkin is unique in that the structure of the protein suggests that it is a classical RBR (Figure 1), 
yet based on cell free assays as well as in situ studies, it contains features of both RING and HECT E3 
ligase activity (Riley et al., 2013). Notably, ligases containing the structures necessary for the trans-
thioesterification reactions during ubiquitin transfer are more susceptible to changes in cell redox status 
(Riley et al., 2013; Groitl and Jakob, 2014).  
Parkin is rich in methionine and cysteine residues, which are the most vulnerable amino acids to 
oxidative modification (Halliwell and Gutteridge, 1989), and HECT domains often contain multiple 
cysteine residues needed for trans-thioesterification (Kee and Huibregtse, 2007). Disruption of these 
catalytic residues by reactive oxygen species (ROS) has been shown to slow or halt substrate 
ubiquitination (Doris et al., 2012). Taken together, these data suggest that there are structural features of 
Parkin that make it uniquely vulnerable to aberrant redox modification or uniquely sensitive to detecting 
changes in redox environment as a mechanism to control bioactivity of the ligase. Indeed, it has been 
hypothesized that one factor that could contribute to the early death of SNpc neurons in PD is the high 
level of ROS produced in these cells (Choi et al., 2003).  
In addition to the conserved RING1, IBR and RING2 domains, Parkin also contains an N-
terminal UBL domain followed by a zinc-binding domain called RING0 (Hristova et al., 2009). Both the 
IBR and RING2 domains bind zinc in a similar topological manner, but differ from the canonical cross-
brace fold conformation of RING1. Parkin's RING finger domains are additional sites of potential 
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structural vulnerability given that within a globular conformation, it binds two zinc ions in a histidine- 
and cysteine-rich motif. This structure promotes protein-protein interactions, but is also biochemically 
unstable and prone to oxidation as well as metal displacement by other divalent cations like cadmium 
and cobalt. The resulting changes in protein structure and function can be rapid, extremely unstable and 
lead to potentially toxic loss or gain of function alterations in activity (Hartwig, 2001). Indeed, metal ion 
disequilibrium has been implicated in environmental toxin induced Parkinson’s disease (Gorell et al., 
1997; Kwakye et al., 2016). 
Through its C-terminal RING domain, Parkin is able to conjugate to a variety of E2 proteins 
(Shimura et al., 2000; Imai et al., 2002; Olzmann and Chin, 2008). The proteins and cofactors that 
regulate binding of Parkin with each of its E2 proteins in vivo remain poorly understood, yet are of great 
importance given that the ability of Parkin to bind unique combinations of E2 proteins regulates the fate 
of ubiquitinated clients (Fiesel et al., 2014). Several disease-associated mutations in PARK2 impair E3 
ligase activity for a selective population of substrates, including growth factors, repair enzymes, and 
structural proteins (Shimura et al., 2000; Zhang et al., 2000; Imai et al., 2002).  
		15	
	
Figure 1: Parkin (PARK2) Structure and Mutations. The PARK2 gene contains few mutations in its 
ubiquitin ligase domain; most of the mutations appear in its RING domains, which bind two zinc ions in 
a histidine and cysteine-rich motif to facilitate the transthioesterfication reaction. (Figure adapted from 
(Riley et al., 2013; Lizama et al., 2017)). 
	
Pathogenic Mutations in Parkin  
Most of the pathogenic Parkin mutations in patients with PD occur in the linker region between 
the UBL and RING1 domains (Figure 1). Indeed, mutations in this region account for 43% of identified 
Parkin pathological changes (Parkinson’s Disease mutations database); however, pathogenic mutations 
have been identified throughout the Parkin protein (Trempe et al., 2013) (Figure 1). For example, the 
RING1 mutant C289G, the RING2 mutant C441R, and the UBL mutant R42P all fail to translocate to 
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depolarized mitochondria (Hampe et al., 2006; Lee et al., 2010; Lazarou et al., 2013). On the other hand, 
the RING1 domain mutant R275W is recruited to mitochondria via a PINK1 dependent pathway yet 
fails to induce mitophagy (Geisler et al., 2010; Narendra et al., 2010) while mutants deficient in E3 
ligase activity such as A240R and T415N not only associate with depolarized mitochondria but also 
induce formation of mitochondrial aggregates (Zhang et al., 2000; Sriram et al., 2005; Lee et al., 2010).  
Mutations have also been found to increase E3 ligase activity of Parkin (Riley et al., 2013; 
Trempe et al., 2013), suggesting that the substrates with which Parkin interacts, the efficacy in which 
substrates are tagged with ubiquitin and delivered to the proteasome for degradation, and other aspects 
of function and localization of this protein are critical determinants of dopaminergic cell survival 
(Seirafi et al., 2015). A testament to this complexity is that not all Parkin substrates accumulate in Parkin 
knockout (KO) mice or PD patients, suggesting that either Parkin-mediated ubiquitination can be 
independent of proteasomal degradation or that redundant E3 ligases, such as CHIP can promote 
proteostasis when Parkin is mutated or absent (Imai et al., 2002; Schlossmacher et al., 2002; Moore et 
al., 2008; Chen et al., 2010).  
 
CHIP Is an Essential U-box Domain E3 Ligase  
In 2002, Imai and colleagues demonstrated that Parkin associates with Heat Shock Protein 70 
(HSP70), where it facilitates ubiquitination and degradation of HSP70 client proteins. Interestingly, this 
interaction is interrupted by expression of the HSP70 co-chaperone and E3 ligase, CHIP. Upon 
dissociation from HSP70, Parkin can instead focus on turnover of the Pael-R receptors and presumably 
other substrates during ER-stress (Imai et al., 2002). Since it was discovered, interest in CHIP has 
rapidly expanded to PD and other neurodegenerative diseases (Kumar et al., 2012; Joshi et al., 2016), as 
acute CHIP overexpression in vitro improves cellular survival by removing damaged proteins and 
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decreasing proteotoxic stress in models of chronic neurological diseases (Dickey et al., 2007a; Rosser et 
al., 2007).  
Despite heightened interest in CHIP, CHIP-specific substrates have been ill-defined and limited 
to known HSC/HSP70 client proteins, which include ataxin-3, p53, mutant tau, mutant huntingtin, and 
cystic fibrosis transmembrane conductance regulator (Arndt et al., 2007; Rosser et al., 2007). Given that 
most CHIP protein-protein interactions were derived from immunoprecipitation experiments that fail to 
capture in vitro and in vivo interactions (Stankiewicz et al., 2010; Kumar et al., 2012), more studies on 
specific binding partners of CHIP during physiological conditions are sorely needed. 
CHIP is a 303 amino acid protein that is highly conserved across species (Ballinger et al., 1999). 
CHIP was originally discovered in a screen of tetracopeptide repeat (TPR) domain-containing enzymes, 
of which many participate in interactions with the heat shock protein family (Ballinger et al., 1999). 
CHIP contains an N-terminal TPR domain, a charged central domain, and a highly conserved C-terminal 
U-box domain that is necessary for its E3 ligase activity (Ballinger et al., 1999; Jiang et al., 2001) 
(Figure 2).  
U-box E3 ligases are far less abundant than RING-finger proteins, with only seven identified in 
the human and mouse proteomes (Hatakeyama et al., 2001). The U-box domain is functionally and 
structurally similar to RING domains, but contains a hydrophobic core that lacks metal-chelating 
residues present in RING domain E3 ligases (Aravind and Koonin, 2000). One possibility is that this 
unique structure renders U-box E3 ligase activity resistant to oxidative modification, and thus a resilient 
scavenger for damaged proteins, lipids, and organelles during stress conditions.  
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Figure 2: CHIP (STUB1) Structure and Mutations. STUB1 is the gene that encodes CHIP, an E3 ligase 
of the RING family with a C-terminal Ubox domain. Several pathogenic mutations were identified in 
CHIP in patients with particular forms of Spinocerebellar Ataxia (SCA). Mutations are located 
throughout the protein, suggesting loss of E3 ligase function is not the only important domain in this 
protein. (Figure adapted from (Pearl et al., 2008; Lizama et al., 2017)). 
CHIP Mutations Result In Unique and Devastating Neurological Dysfunction  
One might suspect that a Parkin surrogate like CHIP would have mild pathological features when 
deleted, similar to Parkin-null mice. In fact, quite the opposite is true. Severe motor impairments, 
mitochondrial failure, cardiovascular abnormalities, and early lethality observed in CHIP deficient 
animals suggest that this protein plays a critical role in aging, stress responsiveness and neurological 
function (Palubinsky et al., 2015). These features stand in stark contrast to Parkin-null mice, which are 
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long-lived and free of major hallmarks of PD or other degenerative diseases (Rial et al., 2014). Under 
conditions of energetic and oxidative stress, heat stress and hypoxia we, and others, have shown that 
CHIP expression is rapidly upregulated (Dai et al., 2003; Kim et al., 2005; Stankowski et al., 2011).  
Within the past five years, whole-exome sequencing has led to the discovery of a number of 
mutations (13 missense; 2 nonsense) in CHIP in patients with recessive ataxia (Casarejos et al., 2014; 
Heimdal et al., 2014; Shi et al., 2014; Synofzik et al., 2014; Bettencourt et al., 2015) (Figure 2). Patients 
with recessive ataxia and spinocerebellar ataxia exhibit a progressive loss of motor control, gait 
abnormalities, and cerebellar atrophy (Heimdal et al., 2014; Shi et al., 2014).  More recently, 
homozygous mutations in the STUB1 gene encoding CHIP resulting in a loss of function in CHIP 
activity have been linked to the rare genetic disorder Gordon Holms Syndrome in which patients present 
with hypogonadism and ataxia (Shi et al., 2014; Rubel et al., 2015). These phenotypes in humans are 
consistent with our observations in which male CHIP-deficient mice are infertile.  
Pathogenic mutations in CHIP are found throughout the protein (Figure 2), and recent functional 
analyses of these mutations in vitro indicate that the consequence of these mutations is structurally 
destabilized CHIP (Pakdaman et al., 2017; Kanack et al., 2018). For example, the TPR mutation E28K 
and the U-box mutation T246M result in decreased CHIP dimerization and increased monomer and 
higher order oligomerization (Pakdaman et al., 2017). Interestingly, the predicted dysfunction of these 
mutations does not always correlate with location of the mutation. For instance, the U-box mutations 
M240T and T246M cause decreased HSP binding in addition to loss of E2 recruitment (Kanack et al., 
2018). Similarly, the TPR mutations N65S and L123V cause decreased E2 recruitment in addition to 
decreaed HSP binding (Kanack et al., 2018). These data reveal that the domains of CHIP work 
cooperatively for HSP-mediated substrate identification and ubiquitination.  
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Figure 3: Loss of CHIP or Parkin Causes Mitochondrial Dysfunction and Energetic Imbalance via 
Redundant and Non-redundant Pathways. Proteomic analysis of whole brains from postnatal day 35 WT 
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and CHIP KO mice was performed to screen for alterations in protein expression. LC-MS/MS shotgun 
analyses of single gel fractions of all proteins were run and the proteins listed (B, C) are the subset of 
those significantly increased or decreased by CHIP KO compared to WT littermates based on spectral 
count data analyzed by QuasiTel (Palubinsky et al., In Preparation; Lizama, Under Review). Proteomic 
data from 2-month-old Parkin KO mouse cortices are described by Periquet and colleagues (Periquet et 
al., 2005). A. Diagram summarizing proteins altered by either CHIP KO or Parkin KO. Proteins 
increased in CHIP KO mice are labeled in red, while proteins decreased by CHIP loss are labeled in 
blue. Proteins increased in Parkin KO mice are labeled in green, while proteins decreased by Parkin loss 
are labeled in purple. B. Glycolytic enzymes pyruvate dehydrogenase (PDH) and lactate dehydrogenase 
(LDH) are increased and decreased, respectively, while mitochondrial pyruvate carrier proteins I and II 
(MPC1/MPC2), which affect pyruvate uptake into mitochondria, are increased by CHIP loss. Acyl CoA 
synthases II and III (ACSS2/ACSS3) are increased in CHIP KO. Loss of CHIP decreases expression of 
the Krebs cycle enzymes 2-oxoglutarate dehydrogenase (αKGDH), malonyl-CoA decarboxylase 
(MCD), and d-2-hydroxyglutarate dehydrogenase (D2-HGD). FAD-dependent oxidoreductase protein I 
(FOXRED1), which is crucial for respiratory complex 1 formation, is also decreased in CHIP KO. C. A 
key enzyme in cardiolipin localization and formation, lysocardiolipin acyltransferase (ALCAT1), is 
decreased in CHIP KO mice. Similarly, prohibitins (PHB1/PHB2), known to control cristae 
morphogenesis and respiratory chain assembly as well as to dictate levels of ROS within mitochondria 
via interactions with cardiolipin are also decreased when CHIP is absent. Three key fission proteins, 
dynamin-related protein 1 (Drp1), mitochondrial fission factor (Mff) and mitochondrial fission 1 protein 
(Fis1) are increased in CHIP KO mice. Figure adapted from (Lizama et al., 2017). 
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To better understand how CHIP deficiency elicits such a devastating phenotype, while Parkin 
deficient models do not, we compared Parkin and CHIP proteomic profiles (summarized in Figure 3). In 
doing so, we hoped to leverage the differences to identify mechanisms by which the CHIP protein may 
prove to be irreplaceable for long-term survival. We hypothesized that the CHIP KO proteomic profile 
will reveal changes critical to mitochondrial function, whereas the Parkin KO proteomic profile would 
reveal changes more in line with events that may only result in pathology after several decades. For 
instance, LDH is decreased in Parkin KO cortices, while PDH is increased, which is the opposite of 
findings in CHIP KO animals (Periquet et al., 2005). Moreover, a critical subunit of Krebs cycle enzyme 
succinate dehydrogenase is increased in Parkin KO (Periquet et al., 2005), while Krebs cycle enzymes in 
our CHIP KO screen are decreased. Taken together, these data underscore a compensatory role for 
Parkin mutated cells to increase metabolic pathways as a mechanism to deal with redox imbalance and 
protein oxidation. On the other hand, proteomic profiles from CHIP KO mice, wherein numerous 
energetics enzymes are decreased, suggest that these animals are unable to compensate. In combination 
with decreases in overall ATP levels in CHIP KO mice (Palubinsky et al., 2015), we suspect that these 
changes underlie the severe motor and behavioral phenotypes of CHIP-deficient mice.	
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Figure 4: Model Depicting PINK1 and CHIP Interaction During Mild OGD That Contributes To Cell 
Survival Through Mitophagy and HSP70 Induction. During normoxia, PINK1 is targeted to 
mitochondria and swiftly cleaved by proteases and degraded via the proteasome. Inactive CHIP and 
Parkin are chiefly cytosolic. During mild OGD, PINK1 stabilizes on the outer mitochondrial membrane, 
recruiting Parkin through its kinase domain activity. Our hypothesis is that CHIP is also recruited to 
mitochondria through PINK1 activity to induce clearance of compromised mitochondria through 
mitophagy. Parallel processes also necessary for survival include activated p66shc and HSP70 induction, 
which negatively regulate the apoptotic pathway. 
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1.4 Rationale 
CHIP, like HSP70, is inducible by ischemic stress, and loss of CHIP results in a uniquely 
devastating neurological phenotype. CHIP deficient animals exhibit pathology resembling early aging 
and degeneration, with increased aggregates of poly-ubiquinated proteins, increased oxidized proteins 
and lipids, and mitochondrial dysfunction. In vitro analyses of CHIP in primary neurons reveal that 
CHIP localizes to mitochondria under severe bioenergetic stress. This project aims to fill gaps in our 
understanding of the molecular cues and consequences of CHIP association with mitochondria during 
physiological and pathophysiological conditions.   
 
1.5 Hypothesis 
We hypothesize that the E3-ligase CHIP is essential for mitochondrial quality control and for 
determining whether neurons are preconditioned to withstand subsequent injury. 
 
1.6 Thesis Specific Aims 
To address the gaps in our understanding of CHIP function after bioenergetic stress and neuronal 
survival, I proposed the following specific aims: 
Aim 1: Test the hypothesis that CHIP expression and localization to mitochondria are events 
associated with neuroprotection afforded by PC. Primary neuronal cultures, immunofluorescence 
imaging, subcellular fractionation, and biochemical analyses of protein expression will be used to 
determine the temporal and spatial localization of CHIP following non-lethal bioenergetic stress.  
Aim 2: Test the hypothesis that mitophagy is associated with cell survival in preconditioned 
neurons. Immunofluorescence imaging and biochemical analyses of protein expression will be used to 
determine the temporal and spatial localization of PINK1 and autophagy-associated proteins, such as 
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LC3. Autophagic activity will also be manipulated during PC through pharmacological agents to assess 
whether mitophagy is protective to neurons following acute bioenergetic stress. 
Aim 3: Test the hypothesis that alterations in CHIP expression and function promote 
mitochondrial dysfunction, disrupt mitophagy, and block neuroprotection. CHIP KO mouse embryonic 
fibroblasts (MEFs), acute siRNA-mediated knockdown of CHIP in WT primary neurons, and expression 
of mutant CHIP plasmids in CHIP KO primary neurons will be used to determine the critical functions 
of CHIP in mitophagy and neuronal survival during bioenergetic stress. 
 
CHAPTER	2	
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C-TERMINUS OF HSC70-INTERACTING PROTEIN LOCALIZES TO MITOCHONDRIA AND IS 
NECESSARY FOR SURVIVAL FOLLOWING ACUTE BIOENERGETIC STRESS 
 
2.1 Abstract 
 C-terminus of HSC70-interacting protein (CHIP, STUB1) is a ubiquitously expressed cytosolic 
E3-ubiquitin ligase. CHIP-deficient mice exhibit cardiovascular stress and motor dysfunction prior to 
premature death. This phenotype is more consistent with animal models in which master regulators of 
autophagy are affected rather than with the mild phenotype of classic E3-ubiquitin ligase mutants. The 
cellular and biochemical events that contribute to neurodegeneration and premature aging in CHIP KO 
models remain poorly understood. Electron and fluorescent microscopy demonstrates that CHIP 
deficiency is associated with greater numbers of mitochondria, but these organelles are swollen and 
misshapen. Acute bioenergetic stress triggers CHIP induction and re-localization to mitochondria where 
it plays a role in the removal of damaged organelles. This mitochondrial clearance is required for 
protection following low-level bioenergetic stress in neurons. CHIP expression overlaps with 
stabilization of the redox stress sensor PTEN-inducible kinase 1 (PINK1) and is associated with 
increased LC3-mediated mitophagy. Introducing human promoter-driven vectors with mutations in 
either the E3 ligase or TPR domains of CHIP in primary neurons derived from CHIP-null animals 
enhances CHIP accumulation at mitochondria. Exposure to autophagy inhibitors suggests the increase in 
mitochondrial CHIP is likely due to diminished clearance of these CHIP-tagged organelles. Proteomic 
analysis of WT and CHIP KO mouse brains from both sexes reveals proteins essential for maintaining 
energetic, redox and mitochondrial homeostasis undergo significant changes in expression dependent 
upon genotype. Together these data support the use of CHIP deficient animals as a predictive model of 
age-related degeneration with selective neuronal proteotoxicity and mitochondrial failure. 
		27	
2.1 Introduction 
 The HSP70 complex is capable of blocking neurodegeneration triggered by a host of genetic 
mutations, physiological events and environmental stressors (Franklin et al., 2005; Gestwicki and Garza, 
2012). HSP70 binding partners alter the localization, activity and expression of the chaperone complex 
itself and its client proteins. E3 ligases, such as Parkin and C-terminus of HSC70-Interacting Protein 
(CHIP), regulate HSP70-mediated protein degradation (Ballinger et al., 1999; Jiang et al., 2001). CHIP 
is a 303 amino acid cytosolic protein that contains an N-terminal TPR domain regulating HSP/HSC70-
docking, a helix-loop-helix domain, and a C-terminal Ubox domain that is necessary for binding to E2-
conjugating enzymes (Ballinger et al., 1999; Jiang et al., 2001; Xu et al., 2008). CHIP is unique among 
E3 ligases in that its expression is induced by acute bioenergetic stress and in post-mortem samples from 
patients with stroke (Stankowski et al., 2011; Lizama et al., 2017). CHIP is also unique in that it forms 
asymmetric homodimers, which have not been observed in other E3 ligase proteins and are only formed 
in higher vertebrates, suggesting it may perform distinctive roles in cell biology (Zhang et al., 2005; Ye 
et al., 2017). 
Further evidence of the unique attributes of CHIP can be found in studies demonstrating that 
mice deficient in CHIP have pervasive dysfunction far more robust than would be predicted based on a 
primary role as a conventional E3 ligase. CHIP insufficiency results in decreased life expectancy, 
profound lipid oxidation, as well as poor performance on behavioral assessments of motor function and 
anxiety (McLaughlin et al., 2012; Palubinsky et al., 2015). Indeed, CHIP knockout (KO) animals are 
unable to complete even simple behavioral assessments given their moribund nature.  
Mutations in CHIP have been identified in patients with an early-onset, recessive form of 
spinocerebellar ataxia, in which mutations in major structural domains confer loss of CHIP function 
(Heimdal et al., 2014; Shi et al., 2014; Synofzik et al., 2014; Bettencourt et al., 2015). Patients exhibit 
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unifying symptoms that include progressive deterioration in muscle coordination and tone, speech 
difficulty, and cerebellar atrophy. Yet, symptom heterogeneity exists among patients with CHIP 
mutations, which include dementia, hypogonadism, and epilepsy. Such variable observations support a 
role for CHIP beyond the cerebellum, where CHIP mutations can cause a multidimensional, 
multisystemic degenerative disease (Hayer et al., 2017). 
In this work, we sought to understand the underpinnings of the devastating phenotype caused by 
CHIP loss by evaluating CHIP’s role in cell signaling employing neuronal models of an acute 
pathophysiological stress. Using a combination of cellular imaging, proteomics, biochemistry, molecular 
targeting and ultrastructural assays, we determined that CHIP deficiency results in radical mitochondrial 
reorganization not seen in other E3 ligase deficient animals. These data reinforce a model in which 
CHIP functions are more in keeping with a role as an essential autophagy regulator than a standard E3 
ligase. Taken together, our data supports the use of these animals as a powerful and robust model of 
neurological dysfunction induced by mitochondrial failure and secondary proteotoxicity. 
 
2.3 Materials and Methods 
Materials and Reagents  
Tissue culture: Fetal bovine serum (SH30070.03) was obtained from Hyclone. Dulbecco’s 
modified Eagle’s medium (DMEM, 11995) with high glucose, minimum essential medium (MEM, 
51200), Neurobasal medium, B27 supplement (17504044), N2 supplement (17502048), 0.25% Trypsin–
EDTA, trypan blue stain 0.4%, and penicillin-streptomycin (15140-122) were purchased from 
Invitrogen. LipoJet In Vitro Transfection Kit (Ver. II) was purchased from SignaGen. 
Western blotting: XT-MOPS running buffer, Tris-Glycine transfer buffer, Criterion Bis-Tris 
gels, Laemmli buffer, and precision plus protein all blue standards were purchased from Bio-Rad 
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Laboratories. Membrane-blocking solution was from Zymed. Hybond P polyvinylidene difluoride 
membranes were acquired from GE Healthcare. Gel Code Blue Stain Reagent and Western Lightning 
Chemiluminescence Reagent Plus were obtained from Thermo Scientific. 
For Western blotting, CHIP (PC711) antibody was purchased from Calbiochem. Antibody for 
p62 was obtained from Cell Signaling Technology (5114). LC3 for Western blotting was obtained from 
MBL International (PD014), and for immunofluorescence LC3 was obtained from Abcam (ab62116). 
HSP70/HSP72 (SPA-811), and HSC70 antibodies (SPA-816) were purchased from Enzo Life Science, 
Inc. PINK1 (BC100-494) and TOM20 (H00009804-M01) antibodies were purchased from Novus 
Biologicals. CHIP (sc-133066) antibody for immunofluorescence was purchased from Santa Cruz 
Biotechnology. 
Unless otherwise stated, all other chemicals were purchased from Sigma-Aldrich. 
 
Experimental Design and Statistical Analysis 
Statistical analyses were performed using GraphPad Prism version 5.03. Error bars indicate 
standard error of the mean (s.e.m) and statistical significance was assessed by one-way ANOVA 
followed by Bonferroni post-hoc analysis (Fig. 1C, Fig. 3A, Fig. 7A, Table 1, Table 2, Table 3), 
unpaired Student’s t-test (Fig. 1E, Fig. 2D, Fig. 4E, Fig. 5A, Fig. 6B, Fig. 7B, Fig. 7C), Mann-Whitney 
analysis (Fig. 4F), or two-way ANOVA (Fig. 5B). Experimental replicates labeled as “n” were derived 
from at least 3 independent cell cultures or animals as indicated and are described further in each 
Methods section.  
 
Maintenance of CHIP WT and KO Mouse Colony 
The Institutional Animal Care and Use Committee at Vanderbilt University Medical Center 
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approved all animal husbandry and experiments. Parental mouse lines were previously described (Dai et 
al., 2003). All mice were maintained on a mixed background of C57BL/6 and 129SvEv for 8 or 9 
generations. Further backcrossing exacerbates the early lethality observed in CHIP KO animals resulting 
in a less than 5% survival at birth. As CHIP KO male mice are sterile, heterozygous matings were used 
to maintain the colony. Generating CHIP KO animals from heterozygous crossings occurs at non-
Mendelian rates because of preferential reabsorption and cannibalism of KO animals that are often 
runted. Genotyping was performed by PCR with DNA from tail clippings using primers for the CHIP 
allele. Primers were purchased from XXIDT and the sequences of the reverse and forward primers used 
are 5’ TGA CAC TCC TCC AGT TCC CTG AG 3’ and 5’ AAT CCA CGA GGC TCC GCC TTT 3’, 
respectively.  
 
Rat Primary Neuronal Culture  
Forebrain cultures were prepared from embryonic day 18.5 Sprague-Dawley rats as previously 
described (Stankowski et al., 2011). Briefly, forebrain was dissociated and the resultant cell suspension 
was adjusted to 750,000 cells/well in 6-well tissue culture plates containing five, 12-mm poly-L-
ornithine-treated coverslips/well. Plating media was composed of 84% (v/v) Dulbecco’s modified 
MEM, 8% (v/v) Ham’s F12-nutrients, 8% (v/v) fetal bovine serum, 24 U/ml penicillin, 24 µg/ml 
streptomycin, and 80 µM L-glutamine.   
Cultures were maintained at 37°C, 5% CO2, and media was partially replaced every 2 – 3 days. 
Glial cell proliferation was inhibited after two days in culture with 2 µM cytosine arabinoside, and cells 
were maintained thereafter in Neurobasal media supplemented with 2% B27 and 2% NS21 until 17 days 
in vitro (Chen et al., 2008). B27 was then removed from the feeding media and cultures were maintained 
in Neurobasal supplemented with NS21 only. This preparation yields a 98% neuronal culture with a 
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mature complement of NMDA receptors (Zeiger et al., 2010). All experiments were conducted between 
DIV20-27.  
 
Neuronal Bioenergetic Stress 
Neurons were exposed to brief periods of bioenergetic stress by removing oxygen and glucose in 
order to trigger mitochondrial stress signaling. Oxygen-and-glucose deprivation (OGD) was performed 
as described with minor modifications (Palubinsky et al., 2015). Briefly, a complete media exchange 
was performed by transferring coverslips into wells containing deoxygenated, glucose-free Earle’s 
balanced salt solution (150 mM NaCl, 2.8 mM KCl, 1 mM CaCl2, and 10 mM HEPES; pH 7.3). 
Cultures were placed in an anaerobic chamber (Billups-Rothberg) for various durations (15–90 minutes) 
at 37°C. OGD was terminated by moving coverslips into 6- or 24-well plates containing MEM, 0.01% 
(w/v) BSA, 2.5% (v/v) HEPES, and 2x N2 (MEM/BSA/HEPES/N2). After 18–24 hours, neuronal 
viability was assessed visually as well as via LDH assays. 
 
Viability Assay of Rat Primary Neurons  
Cell viability was assessed using a lactate dehydrogenase (LDH)-based in vitro toxicity kit 
(Sigma), which colorimetrically determines the amount of LDH released into the culture media from 
dead and dying neurons.In order to account for variation in total LDH content, raw LDH values were 
normalized to the toxicity caused by 90-minute OGD, which, at 24 hours, results in 100% neuronal cell 
death in this system. Viability is also confirmed visually with corresponding brightfield images.   
 
Preconditioning and CHIP siRNA Knockdown in Rat Primary Neurons 
Primary neuronal cultures were grown for 20-25 days in vitro after which they were exposed to 
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low-level bioenergetic stress (15-minute OGD) and immediately returned to normoxia in 
MEM/HEPES/BSA/N2 medium. For studies of mitophagy, neurons were incubated in bafilomycin A1 
(BafA; 1 nM) 30 minutes prior to, during, and after OGD. Twenty-four hours following preconditioning, 
neurons were exposed to 90-minute OGD and viability was determined 24 hours later using LDH assays 
and visual confirmation.  
CHIP small interfering RNA (siRNA) was obtained from QIAGEN Science  (50-
CCAGCTGGAGATGGA GAGTTA-30) (Stankowski et al., 2011). Using the LipoJet Transfection Kit, 
CHIP siRNA (25 nM) and green-fluorescent protein (GFP; 2 𝜇g) were added dropwise into each well of 
a 6-well dish containing neurons in 2 ml of growth medium.  Six hours after addition of transfection 
reagents, cells underwent a complete medium change. CHIP siRNA transfected cells were harvested 24–
72 hours post-transfection in TNEB lysis buffer (50 mM Tris-Cl, pH 7.8, 2 mM EDTA, 150 mM NaCl, 
8 mM β-glycerophosphate, 100 µM sodium orthovanadate, 1% [v/v] Triton X-100, and protease 
inhibitor (P8340) diluted 1:1000) and extracts were prepared for Western blotting. Pilot experiments 
revealed optimal knockdown of CHIP expression at 24 hours (Fig. 5a), and this time point was used for 
all subsequent studies of acute CHIP knockdown. 
 
Western Blotting of Primary Neuronal Lysate 
For in vitro lysates, all cell lysis and harvesting steps took place on ice. Cells were washed twice 
with ice- cold 1x phosphate-buffered saline (PBS), and following the second wash, 150–400 µL of 
TNEB lysis buffer was added.  
Approximately 100-200 µL of lysate was re-suspended in an equal volume of Laemmli buffer 
with β-mercaptoethanol (1:20). Protein samples were heated to 95°C for 10 minutes and stored at -20°C. 
Equal protein concentrations were determined by DC Protein Assay Kit II and samples were separated 
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on 4-12% Criterion Bis-Tris gels. Proteins were transferred to PVDF membranes and blocked in 
methanol for 5 minutes. Following 10 minutes of drying, the membranes were incubated overnight with 
antibodies detecting CHIP, HSP70, HSC70, TOM20, p62, PINK1, or LC3 in 5% non-fat dry milk in 
TBS-Tween (0.1%) or in Membrane Blocking Solution at 4°C. Membranes were washed three times 
with TBS-Tween, and incubated with horseradish peroxidase conjugated secondary antibodies for 1 
hour at room temperature (RT).  Following three washes in TBS-Tween, protein bands were visualized 
using Western Lightning© chemiluminescence plus enhanced luminol reagent. Western blots were 
analyzed using NIH Image (Scion ImageJ) to determine the mean relative densities of each protein band, 
and fold changes were calculated using untreated cultures as controls. Data represent results from at 
least 3 independent experiments as indicated in figure legends. 
 
CHIP WT and KO Mouse Primary Neuronal Culture  
Forebrain cultures were prepared from embryonic day 18 mice generated by heterozygous 
matings as described (Palubinsky et al., 2015). Briefly, mice were decapitated and the entire brain was 
stored individually in Hibernate E medium (HE-Pr; Brain Bits) at 4°C, while tails were processed for 
genotyping. Once PCR was concluded, WT and KO brains were pooled by genotype and dissection 
continued with cortical tissue digestion in 0.025% trypsin for 20 minutes, followed by mechanical 
dissociation. Resultant cell suspensions were plated at 600,000 cells/ml.  
Cultures were maintained at 37°C, 5% CO2 in growth media comprising a volume-to-volume 
mixture of 84% (v/v) DMEM, 8% (v/v) Ham’s F12-nutrients, 8% (v/v) fetal bovine serum, 24 U/ml 
penicillin, 24 µg/ml streptomycin, and 80 µM L-glutamine. Before plating, 2x N2 and 2% NS21 (v/v) 
supplements were added to growth media. Glial proliferation was inhibited after two days in culture via 
the addition of 2 µM cytosine arabinoside, after which cultures were maintained in Neurobasal medium 
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containing 2% B27 (v/v), 2x N2, and 2% NS21 (v/v) supplements with antibiotics for two weeks. One 
week before experiments, neurons were maintained in Neurobasal medium containing 2% (v/v) NS21 
and antibiotics only. All experiments were conducted 20–25 days following dissociation.  
 
CHIP Plasmid Design and Transfection 
Plasmids were generated by and purchased from ProNovus Bioscience, LLC. Mammalian 
expression vectors for hCHIP, hCHIP K30A and hCHIP H260Q are based on pcDNA3.1 (Qian et al., 
2006). The human CHIP promoter sequence was used in order to induce CHIP expression by 
endogenous transcription factors. For detection by immunofluorescence, a mCherry expression sequence 
was added to the 3’ end of the CHIP sequence using a 3xGGGGS linker. Sequences are summarized in 
Appendix A. Using the LipoJet Transfection Kit, plasmid (5 𝜇g) was added dropwise into each well of a 
6-well dish containing neurons in 2 ml of growth medium. Six hours after transfection cells underwent a 
complete medium change, and experiments were carried out the following day.  
 
Immunofluorescence of Primary Neurons 
Cells were fixed in 4% paraformaldehyde (PFA) and then permeabilized with 0.1% Triton X-100 
as previously described (Palubinsky et al., 2015). Primary antibody was diluted in 1% BSA overnight at 
4°C. Cells were washed with 1x PBS for a total of 30 minutes and incubated in Cy-2, Cy-3, or Alexa-
Fluor 350 secondary antibodies (1:500) for 60 minutes at RT. Cells were counterstained with 4,6- 
diamidino-2-phenylindole (DAPi) to observe nuclei. Coverslips were mounted on glass slides using 
ProLong Gold (Fisher; P3693), and fluorescence was observed with a Zeiss Axioplan microscope at 63x 
or 40x, where indicated. 
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Cell Counting and Colocalization of Immunofluorescent Primary Neurons 
Cell counts of primary neuronal cultures prepared for immunofluorescence staining of PINK1 
and MAP2, and of CHIP and MAP2, were carried out using ImageJ FIJI version 2.0.0-rc-43/1.50e. Cell 
counts were performed by two blinded investigators. Statistical significance was determined by two-
tailed unpaired t-test with p<0.05 using GraphPad Prism software. 
Colocalization analysis of mouse primary neurons stained with CHIP and TOM20 were 
performed using Coloc2 in FIJI. Twenty to 30 fields per condition were chosen at random and measured 
by blinded investigators. Background was accounted for by using a Rolling-Ball Background 
Subtraction of 50. Neurons were outlined using the polygon drawing tool. Point Spread Function (PSF) 
was calculated and set to 1.0, and Costes Randomizations was set to 10.  
 
Generation of WT and CHIP KO Mouse Embryonic Fibroblast (MEF) Cultures 
Fibroblast cell lines were developed based on previous protocols (Xu, 2005). Briefly, embryonic 
day 13 mouse pups generated by heterozygous matings were decapitated and internal organs were 
removed. Tail samples were taken and all remaining epidermal tissue was minced and placed in 
individual conical tubes containing 2 mL of 0.25% trypsin-EDTA and digested at 4°C for 18 hours 
followed by 30 minutes at 37°C. Meanwhile tails were processed for genotyping (Palubinsky et al., 
2015). Once PCR and digestion was concluded, WT and KO tissue was pooled, an equal volume of 
MEF media (84% (v/v) DMEM, 10% (v/v) fetal bovine serum, 24 U/ml penicillin, and 24 mg/ml 
streptomycin) was added and the tissue was mechanically dissociated using a 5 mL pipette, triturating 
~20 times. Any remaining tissue was allowed to settle while the supernatant was transferred to a new 
tube. Five mL of MEF media was added to the tissue pellet, trituration was repeated and supernatant was 
collected and added to the initial cell suspension. Trituration and transfer were repeated a final time and 
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the entire resultant cell suspension was plated in a T75 flask and maintained at 37°C, and 5% CO2 until 
cells reached 85% confluency at which point they were passaged. Immortalization was achieved via 
repeated passaging (roughly 25 passages). Following immortalization, all experiments were carried out 
using MEFs between passages 10-20. 
 
Transmission Electron Microscopy of MEFs 
WT and CHIP KO MEFs were grown to 60-80% confluency and fixed in 2.5% glutaraldehyde 
with 0.1 M cacodylate buffer, pH 7.4 at RT then transferred to 4°C overnight. Samples were further 
processed in the Vanderbilt University Medical Center Cell Imaging Shared Resource. Cells were 
washed, scraped, pelleted, and underwent several exchanges of fixative and dehydrating solvents. 
Samples were fixed in 2.5% gluteraldehyde in 0.1 M cacodylate buffer, pH 7.4 at RT for 1 hour then 
transferred to 4ºC overnight. The samples were washed in 0.1 M cacodylate buffer, then incubated 1 
hour in 1% osmium tetraoxide at RT then washed with 0.1 M cacodylate buffer. Subsequently, the 
samples were dehydrated through a graded ethanol series and then three exchanges of 100% ethanol. 
Next, the samples were incubated for 5-minutes in 100% ethanol and propylene oxide (PO) followed by 
2 exchanges of pure PO. Samples were then infiltrated with 25% Epon 812 resin and 75% PO for 30 
minutes at RT. Next, they were infiltrated with Epon 812 resin and PO [1:1] for 1 hour at RT then 
overnight at RT. The next day, samples went through a [3:1] (resin: PO) exchange for 3-4 hours, then 
were incubated with pure epoxy resin overnight. Samples were then incubated in two more changes of 
pure epoxy resin and allowed to polymerize at 60°C for 48 hours. Thin sections (70-80 nm) were cut 
using an ultramicrotome and mounted onto copper grids. The sections were stained with 2% uranyl 
acetate and Reynold’s lead citrate before imaging at 26,000x and 67,000x on an electron microscope 
(Philips T12 equipped with an AMT CCD camera system, FEI).  
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MitoTracker Labeling and Immunofluorescence of MEFs 
WT and CHIP KO MEFs were grown to 60-80% confluency on glass coverslips. MitoTracker 
Orange staining was performed as previously described (Palubinsky et al., 2015). Briefly, MitoTracker 
(Fisher; M7511) was added to live cell cultures at a final concentration of 790 nM and incubated at 37°C 
for 45 minutes. Coverslips were washed with 1x PBS, fixed with 4% (v/v) PFA, permeabilized with 
0.1% Triton X-100, washed again with 1x PBS, and then blocked with 8% (w/v) BSA diluted in 1x PBS. 
After 25 minutes in BSA, coverslips were incubated overnight at 4°C in primary antibody against β-
tubulin diluted in 1% (w/v) BSA. Following primary antibody incubation, cells were washed with 1x 
PBS for a total of 30 minutes and incubated in Alexa 350 secondary antibody in 1% BSA for one hour. 
Cells were next washed for a total of 30 minutes in 1x PBS and coverslips were mounted using Prolong 
Gold.  
Using ImageJ FIJI, a total of 120 WT MEF cells and 169 CHIP KO MEF cells from two 
individual cultures were analyzed. Images were thresholded using an adaptive algorithm and particles 
were analyzed for total count, area, and perimeter. Area and perimeter values were then used to calculate 
mitochondrial circularity (circularity = 4π(area/perimeter2), where values closer to 0 are less circular 
(i.e. ellipses, crescents, and complex tubular structures) and values close to 1 are perfectly circular.  
 
Proteomic Analysis of WT and CHIP KO Brains 
Tissue Preparation and Precipitation 
Whole brains from postnatal day 35 WT mice (4 male, 4 female) and CHIP KO mice (4 male, 4 
female) were removed and immediately placed into a glass dounce containing 1 ml of ice-cold TNEB 
lysis buffer. Brains were homogenized on ice (35 strokes), sonicated at 6 watts for 10 seconds and 
passed through a 40 micron cell strainer then through a 0.2 micron filter affixed to a 10 ml syringe. 
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Protein assays were completed and all samples were adjusted to 2 mg in 1mL of TNEB. Samples were 
precipitated by adding 3 mL of ice-cold ethanol, vortexing and incubating on ice for 3 minutes. 
Following incubation, samples were spun at 3000 x rpm (1819 g) for 10 minutes at 4°C. Upon removal 
of the supernatant, pellets were incubated in a 2:1 mixture of chloroform and ice-cold methanol for 3 
minutes and centrifuged at 3000 x rpm (1819 g) for 10 minutes. Following the spin, pellets were washed 
3 times in 1 ml of ice-cold methanol. After the third wash, pellets were re-suspended in 1 ml of 0.5% 
SDS and sonicated at 6 watts for 10 pulses. Following sonication, 10 µl of sample was added to 8 µl of 
4X sample buffer and 2 µl of 1 M DTT. This portion of the sample was heat denatured at 95°C for 10 
minutes while the rest of the sample was used for protein assay. 
 
Peptide Preparation 
Peptides were prepared as previously described (Ham, 2005). Briefly, equal protein amounts of 
each sample were loaded onto a 10% Bis-Tris gel with empty lanes in between samples and separated at 
180V for 30 minutes. Simply Blue Safe Stain was used to visualize all protein bands and allow for each 
sample to be cut horizontally into ~13 fractions. Each horizontal fraction was then cut vertically into ~1 
mm cubes and placed in a microcentrifuge tube. One hundred µl of 100 mM ammonium bicarbonate 
(AmBic) was added to each fraction tube.  
Samples were reduced with 5 mM DTT in AmBic for 30 minutes at 60°C with shaking. Samples 
were then alkylated with 10 mM iodoacetamide in AmBic for 20 minutes in the dark at RT. Any 
remaining Safe Stain dye was removed with additional 100 µl washes in 50 mM AmBic /acetonitrile 
(1:1, v/v).  Once clear of all dye, gel pieces were dehydrated in 100% acetonitrile. Next, samples were 
rehydrated in 200 µl of 25 mM AmBic containing 300 ng of trypsin gold (Promega) and incubated at 
37oC overnight. Following trypsinization, peptides were extracted from the gel via 3, 20 minute washed 
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in 200 µl of 60% aqueous acetonitrile containing 1% formic acid and evaporated to dryness in vacuo. 
Lastly, peptides were re-suspended in 30% aqueous acetonitrile containing 0.1% formic acid and stored 
at -80oC (Ham, 2005). 
 
Mass Spectrometry 
Protein digests were lyophilized and re-suspended in water prior to solid phase extraction with a 
Waters Oasis HLB cartridge. Prior to use, cartridges were activated with 1 ml of acetonitrile and 
equilibrated with 2 ml of water. Peptides were loaded, washed once with 1 ml water, and eluted with 
70% acetonitrile containing 0.1% formic acid.  Peptides were evaporated to dryness in vacuo, re-
suspended in 10 mM triethylammonium bicarbonate (pH 8.0) and fractionated by bRPLC on an Agilent 
1260 Infinity LC system equipped with an XBridge C18 5 µm 4.6 x 250 mm column. Solvent A was 
aqueous 10 mM triethylammonium bicarbonate at pH 7.4 and solvent B was 10 mM triethylammonium 
bicarbonate in acetonitrile at a flow rate of 0.5 mL/minute. 
Peptides were further fractionated by a gradient in which solvent B was increased from 0% to 
5% from 0 to 10 min, 5% to 35% from 10 to 70 min, 35% to 70% from 70 to 85 min, held at 70% from 
85 to 95 min, and reduced to 0% from 95 to 105 min. The eluted peptides were collected in 64 fractions, 
which were concatenated to fifteen fractions as described (Wang et al., 2011c). Concatenated fractions 
were evaporated to dryness in vacuo and dried samples were re-suspended in 100 uL of 3% acetonitrile 
with 0.1% formic acid for LC-MS/MS analysis. 
LC-MS/MS analyses were performed on a Q Exactive Plus mass spectrometer (Thermo Fisher 
Scientific, Bremen, Germany) equipped with a Proxeon nLC1000 LC (ThermoFisher Scientific) and a 
Nanoflex source (ThermoFisher Scientific).  Peptides were resolved on an 11 cm long column with a 75 
um internal diameter (New Objective, Woburn, MA, PF360–75-10-N-5) packed with 3 µm particle size 
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and 120 Å pore size ReproSil-Pur C18-AQ resin (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) 
over a 70 minute gradient at a 300nL/min flow rate. The gradient was formed utilizing 0.1% formic acid 
in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B) whereby the percentage of B was 
varied as follows: 2% to 5% in 5 min, 5% to 35% over 55 min, 35% to 90% in 3 min, followed by 90% 
for 7 min.  
A single MS1 scan from m/z 300–1800 at 70,000 resolution with an automatic gain control 
(AGC) value of 3e6 and max injection time of 64 msec was recorded as profile data. A top-12 method 
was used, whereby the 12 most intense precursors were automatically chosen for MS2 analysis and a 
dynamic exclusion window of 20 s was employed. For each MS2 scan, a resolution of 17,500, an AGC 
value of 2e5, a max injection time of 100 msec, a 2.0 m/z isolation window, and a normalized collision 
energy of 27 was used and centroid data were recorded.  
Thermo .raw datafiles from LC-MS/MS runs were converted to mzml format using Proteowizard 
version 3.0.5211 (Kessner et al., 2008). The mzml files were searched using MyriMatch version 2.1.132 
(Tabb et al., 2007) and MS-GF+ version 9517 (Kim and Pevzner, 2014) against the mouse Refseq 
database (October 16, 2014). A semi- tryptic search was employed with a maximum of four missed 
cleavages allowed. A fixed carbimidomethyl modification on Cys, a variable oxidation on Met, and a 
pyro-glu on Gln were allowed with a maximum of 2 dynamic modifications per peptide.  Precursor ions 
were required to be within 15 ppm of expected values and fragment ions within 20 ppm. A target-decoy 
search was employed using a reverse sequence database to allow calculation of FDR for peptide-spectral 
matches. The final protein list was assembled following the rule of parsimony in IDPicker 3 version 
3.1.643.0 (Ma et al., 2009) at a protein FDR of <1%. This protein list was then analyzed for spectra 
which were found to be 2 fold or greater different between WT and KO CHIP mice. 
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2.4 Results 
Low-level Bioenergetic Stress Induces CHIP Expression 
In neuron enriched cultures, bioenergetic stress induced by 15 minutes of OGD initiates a robust 
defensive program with sufficient magnitude to significantly decrease the cell death associated with a 
subsequent exposure to a normally lethal 90-minute period of OGD (Figure 5A). Consistent with prior 
reports, both bright-field photomicrographs of live cells (Figure 5B) and LDH release assays (Figure 
5C) reveal that low-level bioenergetic stress protects approximately 45% of neurons from subsequent 
injury (McLaughlin et al., 2003; Brown et al., 2010; Zeiger et al., 2010). Importantly, this stressor does 
not result in neuronal cell death, as evident by phase-bright somas and intricate processes that are 
indistinguishable from control cells (Figure 5B). To examine the temporal and spatial time-course of 
CHIP expression in cells primed with by low-level bioenergetic event, we harvested neurons at various 
time points following 15 minutes of OGD. CHIP expression begins to increase within 1 hour (1.8-fold 
±0.4 above control, Table 1), peaks 6 hours after stress (2.8-fold ±0.8 above control), and remains 
elevated at 24 hours (1.7-fold ±0.3 above control; Figure 5D). Notably, increases in HSP70 expression 
lag behind CHIP, peaking between 6 and 18 hours (2.5-fold ±0.2 above control, p=0.01) and returning to 
baseline levels at 24 hours (0.9-fold of control ±0.4; Figure 5D). 
To determine the percentage of neurons that express CHIP in response to bioenergetic stress, we 
stained neurons 24 hours following 15-minute OGD. While we observed an increase in total CHIP 
expression via Western blot, by ICC we observed that CHIP is expressed in 49% of mildly stressed 
neurons, which was not significantly different from control cultures (Figure 5E). Given that CHIP 
expression undergoes temporal and spatial changes in response to stress (Figure 5C; (Stankowski et al., 
2011; Palubinsky et al., 2015), we suspect that using this method failed to capture the dynamic turnover 
and subcellular localization of CHIP at a static timepoint of 24 hours post-OGD.  
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In previous work, mitochondria isolated from CHIP KO animals exhibit dysfunction in response 
to calcium challenge, suggesting CHIP is important for mitochondrial homeostasis during stress 
(Palubinsky et al., 2015). To test this hypothesis, we used the mitochondrial import receptor, TOM20 to 
label mitochondria and co-stained for CHIP in cells exposed to bioenergetic stress. We observed 
increased overlap of CHIP with TOM20-positive mitochondria as early as 3 hours after acute stress 
(data not shown) that was maximal at 6 hours (Figure 5F, overlap of CHIP and TOM20 in white). Taken 
together, these data demonstrate that CHIP localizes to mitochondria during the period in which neurons 
are upregulating endogenous protective pathways and HSP70. We next sought to determine how 
mitochondrial quality control signaling is impacted by low-level bioenergetic stressors.  
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Figure 5: Low-Level Bioenergetic Stress Induces CHIP Expression. (A) Primary rat forebrain cultures 
were exposed to 15’ OGD. Twenty-four hours later, neurons were exposed to 90’ OGD, following 
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which cells were returned to growth media. Cell survival was assessed via LDH 24h later. (B) 
Representative photomicrographs taken 24h after 15’ OGD (PC) reveal many phase-bright neuronal 
somas and intact processes that are indistinguishable from Control. Twenty-four hours after 90’ OGD, 
there were no phase-bright neurons, indicative of total neuronal death. Cultures that were preconditioned 
(PCà90’OGD) contained more phase-bright neurons and intact processes compared to 90’ OGD. (C) 
LDH release was measured, and values were normalized to 90’ OGD (100% cell death) in naive cells. 
Data represent the mean from four independent experiments analyzed by one-way ANOVA with 
Bonferroni post-hoc testing. Δ Denotes statistical significance (p<0.05), comparing 90' OGD to control 
cultures. * Denotes statistical significance comparing PC➝90' and all other groups (p<0.05). (D) 
Neurons exposed to 15' OGD were harvested 1, 3, 6, 18, or 24h later. Whole cell lysates were probed 
with antibodies against HSP70 and CHIP, as well as HSC70 and β-Tubulin as loading controls. 
Quantification is summarized in Table 1. (E) Twenty-four hours after PC, cultures were probed with 
antibodies to CHIP, MAP2, and DAPI. Cell counts were performed by blinded investigators. Basal 
CHIP expression is observed in 49% of MAP2-positive neurons and is not significant from control post-
PC (n=3, unpaired t-test p>0.05). (F) Preconditioned neurons were PFA-fixed after 6h of recovery and 
probed for CHIP (magenta), TOM20 (green), and DAPI (blue). 
	
Table 1: Quantification of CHIP and HSP70 After Mild Bioenergetic Stress. Neurons exposed to 15' 
OGD were harvested 1, 3, 6, 18, or 24h later. Whole cell lysates were probed with antibodies against 
HSP70 and CHIP, with HSC70 and β-Tubulin as loading controls (Figure 5D). Bands were quantified 
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by ImageJ FIJI densitometry analysis. Values summarized in the table are the average band intensity 
relative to Control ± the standard error of the mean (s.e.m). Significance was determined using one-way 
ANOVA with Bonferonni post-hoc analysis. Increased HSP70 expression following mild bioenergetic 
stress was statistically significant at 6h post-OGD (p=0.01). CHIP increases early following OGD and 
remains increased above control levels, although the differences were not statistically significant. 
 
Low-level Bioenergetic Stress Changes Mitochondrial Morphology and Increases Expression of the 
Mitophagy Related Protein PINK1 
Mitochondria are dynamic organelles that undergo continuous fission and fusion events, as well 
as mitophagy. All of these processes are induced by various cell stressors, including mild hypoxic stress 
(Archer, 2013). To determine the morphology of mitochondria during low-level bioenergetic stress, rat 
primary neurons were exposed to 15 minutes of OGD then visualized with TOM20 immunostaining 24 
hours later. 
We found that although control and mildly stressed neurons exhibit healthy, structurally similar 
processes and nuclei based on MAP2 and DAPi fluorescence, mitochondrial localization is profoundly 
impacted by bioenergetics (Figure 6A). Mitochondria are typically well dispersed within the soma and 
along processes. However, low-level stress increased the number of fragmented mitochondria along 
neuronal processes as well as clustering of mitochondria within the soma. 
During cell stress, mitochondrial membrane potential is compromised, allowing retention and 
accumulation of PINK1 on the outer mitochondrial membrane (Greene et al., 2012; Jin and Youle, 
2013). The kinase activity of PINK1 recruits E3 ligases, such as Parkin, as well as the autophagy protein 
LC3, which seeds formation of an autophagosome around the mitochondrion (Kawajiri et al., 2010; 
Klionsky et al., 2016). 
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We hypothesized that stabilization of PINK1 and mitochondrial clearance may participate in 
neuroprotection by priming neurons for a secondary stress. To test this hypothesis, whole cell lysate was 
collected 3, 6, and 24 hours following bioenergetic stress and full-length, stabilized PINK1 was found to 
rapidly increase and remain elevated for 24 hours (3.3-fold ±2.1 above control; Figure 6B, Table 2). 
To further elucidate the extent of bioenergetically-induced PINK1 stabilization in neurons, we stained 
for PINK1 24 hours following 15 minutes of OGD and found a significant increase in the total number 
of PINK1 positive cells compared to untreated cultures (28% increase; n=3, p=0.01) (Figure 6C & D). 
The number of MAP2-positive neurons does not change after PC, consistent with previous data (Figure 
5); however, we observe that the underlying neuropil undergoes remodeling that is made apparent using 
immunofluorescence techniques (Figure 6C). Given that PINK1 is a rapid sensor of mitochondrial 
dysfunction, this data is consistent with our prior observation that 15 minutes of OGD, while a mild 
bioenergetic stress resulting in no neuronal cell death (Figure 5B, 1C), does cause substantive energetic 
and oxidative stress (Stankowski et al., 2011). 
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Figure 6 Low-Level Bioenergetic Stress Results in Changes in Mitochondrial Morphology and Increased 
Expression of the Mitophagy Related Protein PINK1. (A) Rat primary forebrain neurons were exposed 
to 15’ OGD (PC), probed with antibodies recognizing TOM20 (magenta) and MAP2 (green), and were 
counterstained with nuclei marker DAPI (blue). PC was associated with fragmented mitochondria 
(magenta) while neuronal processes (green) remained intact, consistent with the preservation of cell 
viability. (B) Mitochondrial stress was assessed by evaluating stabilized PINK1 3, 6, or 24 hours after 
PC. Whole cell lysates were probed with antibodies against PINK1 and the mitochondrial outer 
membrane protein TOM20, as well as HSC70 and β-Tubulin as loading controls. Quantification is 
summarized in Table 2. (C) Using immunofluorescence, PINK1 (magenta) and MAP2 (green) staining 
revealed high levels of somatic PINK1 staining around nuclei (blue) of preconditioned cells, consistent 
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with the overall elevation in PINK1 signal in panel (B). (D) Cell counts of PINK1 positive neurons were 
performed by blinded investigators. PINK1 can be observed in 38% of MAP2-positive neurons at 
baseline. After PC, the number of neurons expressing stabilized PINK1 significantly increases to 68% of 
neurons (n=3, p=0.01; unpaired t-test).     
	
Table 2 Quantification of PINK1 and TOM20 after Mild Bioenergetic Stress. Neurons exposed to 15' 
OGD were harvested 3, 6, or 24h later. Whole cell lysates were probed with antibodies against PINK1, 
TOM20, with HSC70 and β-Tubulin as loading controls (Figure 6B). Bands were quantified by ImageJ 
FIJI densitometry analysis. Values summarized in the table are the average band intensity relative to 
Control ± the standard error of the mean (s.e.m). Significance was determined using one-way ANOVA 
with Bonferonni post-hoc analysis. PINK1 expression increases by 3h following OGD and remains 
increased above control levels, although the differences were not statistically significant. 
	
Autophagic Signaling Is Required for Achieving a Protective Response 
Some E3 ligases, such as Parkin, play critical roles in promoting mitophagy in response to stress, 
but likely not in the normal clearance of these organelles (Kubli et al., 2013). We therefore sought to 
determine the role of CHIP in both pathophysiological and physiological mitophagy in neurons. 
To determine the contribution of mitophagy, we used the autophagy inhibitor, bafilomycin A1 
(BafA) to prevent lysosome acidification during our mild bioenergetic stress (Klionsky et al., 2016). The 
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next day, we treated rat primary neurons with 90 minutes of OGD, which is typically lethal, and 
assessed cell death 24 hours later. Neurons treated with 1 nM BafA during the priming event exhibited 
increased cell death following secondary stress compared to those that only received the initial, mild 
bioenergetic priming stress (n=4, p<0.05; Figure 7A). 
By measuring CHIP and HSP70 expression in this paradigm, we determined both proteins were 
highly expressed in primed neurons in the presence of BafA, with CHIP expression significantly 
increased by 24h (1.4-fold ±0.1 above control, p=0.01; Figure 7B, Table 3). PINK1, while increased 
after OGD in the presence or absence of BafA, was not statistically different. To determine autophagic 
flux, we quantified Western blot band intensities of LC3-I and LC3-II (Klionsky et al., 2016) and 
observed that LC3-II accumulated in cultures preconditioned with BafA co-treatment, revealing 
impeded autophagic flux (LC3-II:LC3-I is 2.1-fold ±0.3 above control, p=0.03; Figure 7B, Table 3). We 
also observed dramatically increased accumulation of LC3- and CHIP-positive autophagosomes in 
neurons following low-level OGD (Figure 7C: Middle). This effect was further augmented with BafA 
treatment (Figure 7C: Right). Taken together these data suggest that CHIP localization to mitochondria 
coincides with mitophagy and that mitophagy is a critical component of the neuroprotection afforded by 
preconditioning. 
		50	 	
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Figure 7 Autophagic Signaling Is Required for Achieving a Protective Response. Neurons were exposed 
to 15' OGD in the presence or absence of the Bafilomycin A1 (BafA, 1 nM), a drug that blocks vacuolar 
ATPases, inhibiting fusion between autophagosomes and lysosomes. (A) Survival was assessed by LDH 
release 24h after subsequent 90' OGD as described in Figure 5A.  Blocking autophagy resulted in 85% 
cell death, a significant increase compared to PC neurons without BafA. Values were normalized to 90’ 
OGD. Data represent the mean from 4 independent experiments. *denotes significance compared to 
preconditioned cells (p<0.05). (B) Control neurons, neurons treated with BafA, preconditioned neurons 
(PC) and neurons preconditioned plus BafA (PC+BafA) were harvested for Western blotting 24 hours 
after treatment. Whole cell lysate was probed for CHIP, HSP70, LC3, PINK1, p62, TOM70, HSC70, 
and β-Tubulin. Accumulation of LC3-II and CHIP was evident in PC+BafA. Quantification is 
summarized in Table 1.  (C) Preconditioned neurons were fixed 6h after PC in the presence or absence 
of BafA, and CHIP localization was evaluated by immunofluorescence (magenta). Autophagosomes 
were labeled with LC3 (green), and mitochondria labeled with TOM20 (blue). Images were taken at 
63x; teal boxes were magnified to show regions of LC3 staining around CHIP-positive mitochondria. 
Overlap of the three labels results in white.  
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Table 3 Quantification of Proteins Following Autophagy Inhibition During Mild Bioenergetic Stress. 
Control neurons and neurons exposed to bafilomycin A (BafA, 1 nM), 15' OGD, or 15’ OGD +BafA 
were harvested 24h post-treatment. Whole cell lysates were probed with antibodies against HSP70, 
CHIP, PINK1, TOM20, p62, and LC3, with HSC70 and β-Tubulin as loading controls (Figure 7B). 
Bands were quantified using ImageJ FIJI using densitometry analysis. Values summarized in the table 
are the average band intensity relative to Control ± the standard error of the mean (s.e.m). Significance 
was determined using one-way ANOVA with Bonferonni post-hoc analysis. While HSP70, PINK1, 
TOM20, and p62 expression increase following OGD and BafA treatment, they are not found to be 
statistically significant. The ratio of LC3-II to LC3-I increases following mild bioenergetic stress and 
was statistically different when co-treated with BafA (p=0.01). CHIP expression also increases after 
OGD with BafA co-treatment (p=0.01). 
	
CHIP Deficiency Increases Mitochondrial Number and Changes Mitochondrial Morphology 
Given the increased CHIP localization to mitochondria during mild bioenergetic stress, we 
sought to determine if CHIP also played a role in mitochondrial homeostasis during physiological 
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conditions. Mouse embryonic fibroblasts (MEFs) provide higher resolution imaging of mitochondrial 
morphology than neurons, as MEFs are large, flat, and non-polarized. We hypothesize that changes in 
mitochondrial morphology caused by CHIP loss is pervasive and will manifest even in mitotic, 
peripheral cell types. 
WT and CHIP KO MEFs were prepared for transmission electron microscopy (tEM) after 15-20 
passages under normal growth conditions where both cell lines underwent mitosis after ~30 hours. tEM 
imaging of WT MEFs reveal large, round mitochondria with intact membranes and many thin cristae 
(Figure 8A-C). These cells contain large lysosomes and the endoplasmic reticuli appear tubular 
throughout the slice. CHIP KO MEFs were appreciably different from WT cells in that the majority of 
mitochondria had thick, swollen cristae and smaller matrices (Figure 8D-F) consistent with 
mitochondrial stress and swelling even though the cells proliferated normally. KO MEFs also contained 
fewer lysosomes and irregularly-shaped endoplasmic reticuli. 
To quantify the extent of mitochondrial morphological changes, we performed MitoTracker 
Orange staining in WT and CHIP KO MEFs and prepared them for ICC with β-tubulin co-stain. Using 
ImageJ FIJI, we quantified mitochondrial number, area, and perimeter. Area and perimeter values were 
then used to calculate mitochondrial circularity, where values closer to 0 are less circular (i.e. more 
tubular) and values close to 1 are perfectly circular. 
CHIP KO MEFs contained significantly greater numbers of mitochondria than WT (Figure 8G, 
p<0.0001). Given the large amount of variability in CHIP KO mitochondrial number, we hypothesize 
that during the division phases of mitosis, CHIP KO fibroblasts undergo bioenergetic, mitophaghic and 
proteostatic pressures which result in highly variable mitochondria not observed in normal fibroblasts. 
These data are consistent with previous reports that mitochondrial mass is largely affected by 
proliferation and increased oxidative stress (Lee et al., 2002).  
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We observed that relative frequency distributions for mitochondrial circularity are skewed in 
CHIP KO MEFs, with higher frequencies for more elongated mitochondria (circularity <0.3) than in WT 
(Figure 8H). This finding of increased non-circular mitochondria in KO cells seems to contrast our tEM 
results, in which mitochondria appear smaller and lack complex structure. However, EM analysis is 
dependent on 2D transverse sectioning of cells, which does not capture the complex structure of 
mitochondrial branching or length. 
	
Figure 8: CHIP Deficiency Results in Significantly Increased Mitochondrial Number with Abnormal 
Morphological Features. Immortalized MEFs were cultured from WT and CHIP KO mice. (A,B,D,E) 
MEFs were grown to 60-70% confluency and fixed for tEM. Sections (70-80 nm) were imaged at 
26000x (A, D; Scale bar, 500 nm) and 67000x (B, E; Scale bar, 200 nm). (A, B) WT MEFs have well-
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defined mitochondrial membranes and thin inner membranes forming cristae. (D, E) KO MEFs have 
smaller mitochondria containing unstructured cristae and thick inner membranes. (Endoplasmic 
Reticulum, E; Lysosome, L; Mitochondria, M). (C, F) MEFs were stained with MitoTracker Orange and 
PFA-fixed. Images used for measuring mitochondrial Count, Area, and Perimeter were taken using a 
Zeiss Apotome (63x) and analyzed via ImageJ. Scale bar, 20 µm. (G) KO MEFs exhibit significant 
increases in MitoTracker Orange-positive mitochondria per cell compared to WT (p<0.0001, *denotes 
significance). (H) Circularity was calculated using Area and Perimeter measurements where values 
closer to 0 indicate elongated or tubular mitochondria, and a value of 1 indicates a perfect circle. Values 
were multiplied by 100 in order to generate histograms. KO MEFs exhibit significantly increased 
numbers of elongated mitochondria (p<0.0001, ^ denotes a shift in relative frequency compared to WT). 
Graphs represent data from duplicate coverslips per genotype from two independent cultures, with 
significance determined via Mann-Whitney analysis. 
	
CHIP Plays a Critical Role in Acute Neuroprotection 
Given that CHIP plays a critical role in maintaining normal mitochondrial morphology and its 
expression increases in response to acute stress (Palubinsky et al., 2015), we hypothesized that CHIP is 
necessary for neuroprotection. Since chronic loss of CHIP causes profound changes in the proteome and 
intracellular milieu (Min et al., 2008; Palubinsky et al., 2015), we chose to acutely deplete rat primary 
neurons of endogenous CHIP using siRNA to test this hypothesis. We achieved approximately 67.5% 
knockdown of CHIP 24 hours post-transfection compared to control (p=0.0258, n=4; Figure 9A). By 48 
hours post transfection, CHIP expression was not significantly different from control (p=0.661, n=4; 
Figure 9A). Importantly, CHIP siRNA caused no changes in cellular morphology or cell viability 
(Figure 9B) compared to neurons that were treated with vehicle.  
		56	
To test the effect of CHIP deficiency during neuroprotective priming, we transfected neurons 
with CHIP siRNA followed 24 hours later (during optimal CHIP knockdown) by a mild bioenergetic 
stress. CHIP depletion did not affect viability after low-level (15 minute) OGD compared to non-
transfected neurons (Figure 9B). We next sought to determine the effect of CHIP depletion on 
neuroprotection against a lethal stressor. We subjected CHIP-depleted cultures to low-level OGD 
followed by 90-minute OGD 24 hours later. Although CHIP expression was uninhibited during 90 
minutes of OGD, cells that were depleted of CHIP during the priming event were not afforded 
neuroprotection and exhibited levels of cell death comparable to lethal, 90 minute OGD, alone (Figure 
9B). 
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Figure 9: CHIP Expression Is Required for Achieving a Protective Response. Neurons were treated with 
vehicle (C), transfected with GFP (G), or transfected with GFP and 20 nM of CHIP siRNA (si). Neurons 
were harvested either 24 or 48 hours later, and Western blotting was performed for CHIP using HSC70 
and β-Tubulin as loading controls. (A) Maximal silencing of CHIP expression (67.5%, p=0.026, n=4) 
was achieved 24 hours post-transfection, and this time point was chosen to determine whether blocking 
CHIP attenuated PC-induced neuroprotection. CHIP expression by 48h was not significantly different 
from control (p=0.66, n=4). No significant differences in HSC70 (p=0.97, n=4) or β-Tubulin expression 
were observed (p=0.55, n=4). (B) LDH released from dead or dying cells was assessed 24 hours after 90' 
OGD as described in Figure 9. Raw absorbance values were normalized to values obtained from 90’ 
OGD, which leads to 100% cell death. LDH release data revealed that CHIP-deficient neurons were far 
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less likely to survive 90' OGD, even though they had been preconditioned. Data represent the mean from 
3 independent experiments, with significance determined by two-way ANOVA and Bonferroni post-hoc 
analysis. *denotes significance as compared to non-transfected cells with p<0.05. 
 
Mitochondrial Localization of CHIP Is Independent of its E3 Ligase Activity and HSP70 Binding 
To eliminate changes attributed to cell passage and mitosis as observed in MEFs, we next used a 
superior physiological model of acute neuronal stress, subjecting post-mitotic CHIP KO primary 
neuronal cultures to a mild bioenergetic stress. We predicted that CHIP KO neurons would exhibit 
severe deficits in mitochondrial quality and that, even when CHIP was reintroduced into KO cells, it 
would colocalize to mitochondria in control cells, given that they had lacked CHIP prior to transfection. 
To test these hypotheses, we exposed WT and CHIP KO neurons to 15 minutes of OGD and 
assessed mitophagic processes using immunofluorescence staining for TOM20 as a mitochondrial 
marker and LC3 as a signal for autophagosome formation 6 hours after the bioenergetic stress. WT 
neurons exposed to acute stress exhibited LC3-positive autophagosomes throughout the cells that 
contain both mitochondria and CHIP (Figure 10A). In contrast, KO neurons exhibit much more 
pervasive somatic redistribution of mitochondria following the stressor compared to WT controls 
(Figure 10A). In CHIP-deficient cells, we also observed elongated mitochondria that colocalize with 
LC3 after OGD, with fewer rounded autophagosome structures. Taken together with Figure 8, these data 
suggest that CHIP is necessary for maintaining mitochondrial morphology and suggest a role for CHIP 
in the mitophagic removal of dysfunctional organelles. 
Quantification of colocalization was performed using FIJI Coloc2 on immunofluorescence 
images of WT neurons expressing TOM20 and endogenous CHIP. We found that some CHIP:TOM20 
colocalization is maintained at basal levels (Figure 10B). After mild bioenergetic stress, we find that 
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CHIP:TOM20 colocalization does not change relative to control levels. We suspect that mitophagy 
occurs rapidly after the initiation of OGD.  
	
Figure 10: CHIP Localizes to Mitochondria At Baseline and After Bioenergetic Stress. (A) WT and 
CHIP KO primary neurons were treated with 15' OGD and fixed 6h later. Cultures were probed with 
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antibodies targeting TOM20 (blue), CHIP (red), and LC3 (green). Scale bar, 20 µm. CHIP and TOM20 
colocalization was analyzed using Coloc2 (FIJI). KO neurons exhibit elongated mitochondria that 
colocalize with LC3 after OGD, with fewer rounded autophagosome structures compared to WT. (B) 
WT neurons exhibit a baseline colocalization of CHIP and mitochondria with an average Pearson 
Correlation Coefficient (PCC) of 0.15, which was not significantly different post-OGD (PCC=0.12).  
As CHIP does not contain a canonical mitochondrial targeting sequence, we next sought to 
determine the structural domains necessary for CHIP localization to mitochondria. CHIP contains two 
primary functional domains: the N-terminal Tetracopeptide Repeat (TPR) domain that binds to HSPs 
and other TPR domain-containing enzymes and the C-terminal Ubox domain required for E3 ligase 
activity (Ballinger et al., 1999; Jiang et al., 2001). Mutations identified in patients with spinocerebellar 
ataxia are located in multiple domains of CHIP, leading to loss of either chaperone function or ubiquitin 
ligase activity (Heimdal et al., 2014; Shi et al., 2014; Synofzik et al., 2014; Bettencourt et al., 2015). If 
CHIP acts in ways similar to Parkin, the C-terminal E3 ligase domain would be necessary for mitophagy 
and H260Q mutants would accumulate LC3-positive organelles but fail to remove them. We also 
introduced a TPR K30A mutation and hypothesized that if HSC/HSP70 binding is required for 
mitophagy, K30A transfected cells would have no colocalization of constructs with mitochondria under 
baseline conditions or during bioenergetic stress. 
We cultured primary forebrain neurons from CHIP KO mice and transfected plasmids expressing 
non-mutated CHIP driven by a human promoter (hCHIP), Ubox mutant hCHIP (H260Q), or TPR mutant 
hCHIP (K30A) - each fused to a mCherry expression sequence. Transfected neurons were then exposed 
to mild bioenergetic stress (15 minute OGD) and mCherry localization was assessed after 6 hours of 
recovery via ICC for TOM20 and LC3. We observed transfection of ~20% of neurons. Under baseline 
conditions TOM20-positive mitochondria were well-dispersed, elongated, and within a network along 
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processes. Six hours after a mild bioenergetic stress, staining for all inducible constructs of CHIP under 
the human promoter was evident (Figure 11A-C). Both human promoter-driven, non-mutated CHIP and 
the same construct with a H260Q Ubox inactivation mutation colocalized with mitochondria following 
stress (Figure 11A, 7C). Interestingly, transfected CHIP with a K30A HSP70-interaction site mutation 
also colocalized with mitochondria that were in close proximity to LC3 labeling (Figure 11B). These 
data suggest that neither E3 ligase activity nor HSP family binding is necessary for CHIP to localize to 
mitochondria. 
Quantification of colocalization was performed using FIJI Coloc2 on immunofluorescence 
images of KO neurons expressing TOM20 and transfected hCHIP in KO neurons. When neurons from 
CHIP KO animals were transfected with either K30A mutant (Figure 11B) or H260Q mutant CHIP 
(Figure 11C), we observed a significant increase in CHIP:TOM20 colocalization after OGD. Similar to 
WT neurons (Figure 10), we did not observe a difference in colocalization between control and after 
bioenergetic stress in KO neurons transfected with the non-mutated human CHIP plasmid (Figure 11A). 
We did observe that hCHIP localizes to mitochondria at baseline in CHIP KO cultures likely due to the 
severe disruption of mitochondrial morphology, as seen in CHIP KO MEFs (Figure 8), as well as the 
limited calcium buffering ability noted in isolated CHIP KO mitochondria (Palubinsky et al., 2015). 
Because we see no significant difference in mitochondrial localization of endogenous (Figure 
10B) or non-mutated CHIP (Figure 11A) after OGD, we suspect that active CHIP-mediated mitophagy 
may be occurring rapidly following stress. Given that functional autophagic processes are necessary for 
mitochondrial clearance, we hypothesize that the increases observed in mutant CHIP colocalization to 
mitochondria after mild bioenergetic stress are likely due to deficient clearance and subsequent 
accumulation of CHIP-tagged mitochondria. To test this, KO neurons transfected with non-mutated 
hCHIP were treated with BafA to block autophagosome fusion with lysosomes following bioenergetic 
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stress (Figure 11A). Indeed, hCHIP increases colocalization with mitochondria after low-level stress 
when autophagy is blocked compared to control and low-level OGD alone, suggesting that CHIP-tagged 
mitochondria are directed for autophagy (Figure 11A). Taken together, these data suggest that functional 
Ubox and TPR domains are essential for clearance of mitochondria after bioenergetic stress but not for 
mitochondrial localization. 
		63	
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Figure 11 CHIP is Necessary for Maintaining Mitochondrial Quality Control After Stress, Yet 
Mitochondrial Localization of CHIP is Independent of the TPR and Ubox Domains. (A) CHIP KO 
neurons were transfected with CHIP (hCHIP) (A), K30A (B), or H260Q (C). Twenty-four hours after 
transfection, cultures were exposed to 15' OGD or 15’ OGD +BafA (1 nM) and PFA-fixed at 6h. 
Cultures were probed with antibodies targeting TOM20 (blue) and LC3 (green). Red fluorescence is 
emitted from the mCherry tag linked to transfected CHIP. Scale bar, 20 µm. (A) KO neurons transfected 
with non-mutated hCHIP (KO+hCHIP) exhibit baseline CHIP:TOM20 colocalization (PCC=0.26) that 
does not significantly differ post-OGD (PCC=0.21). Cotreatment with BafA significantly increases 
CHIP:TOM20 colocalization post-OGD (PCC=0.38) compared to control and OGD alone. (B) KO 
neurons transfected with K30A (KO+K30A) demonstrate increased colocalization post-OGD 
(PCC=0.43) compared to control (PCC=0.20). (C) KO neurons transfected with H260Q (KO+H260Q) 
show increased colocalization post-OGD (PCC=0.42) compared to control (PCC=0.28). *Denotes 
significance of p<0.01, and ** p<0.0001. 
 
Loss of CHIP Changes the Expression of Critical Bioenergetic Enzymes and Mitochondrial Quality 
Control Proteins 
  Mitochondrial transport failure, altered organelle dynamics and changes in structure and function 
have been implicated in the primary pathology of an increasing number of neurodegenerative diseases 
(Morotz et al., 2012; Yan et al., 2013; Serrat et al., 2014; Zhang et al., 2015). Proteomic analyses of 
whole-brains harvested from PND35 WT and CHIP KO mice revealed a number of proteins essential for 
mitochondrial trafficking and energetic homeostasis that are significantly altered in CHIP KO animals 
compared to WT (Table 4).  
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The greatest change observed was a 10-fold increase in the expression of ganglioside-induced 
differentiation associated protein (Gdap-1). Like CHIP, Gdap-1 lacks a canonical mitochondrial 
targeting sequence, but functions as an essential mitochondrial outer membrane protein regulating 
mitochondrial structure and function (Niemann et al., 2005; Otera and Mihara, 2011). Artificially 
increasing Gdap-1 expression in cell lines results in mitochondrial hyper-fission without overt toxicity, 
while driving the expression of fusion proteins such as mitofusin 1 can reverse this phenotype (Niemann 
et al., 2005). The 10-fold increase in Gdap-1 observed in CHIP KO mice should drive mitochondrial 
fission and therefore manifest as small circular mitochondria. Yet our imaging analysis and 
quantification of mitochondria from CHIP KO MEFs demonstrate elongated and misshapen organelles. 
This suggests that Gdap-1 upregulation, while significant, is unsuccessful at driving fission in a CHIP-
deficient model.  
While less well understood in the context of mitochondrial dynamics, the dynamin protein family 
is essential for endocytosis, organelle fission and fusion and vesicle formation (Antonny et al., 2016). 
Dynamin 1 and 3 are CNS-specific and are highly expressed in neurons (Romeu and Arola, 2014). We 
observed a 7.5-fold increase in expression levels of Dynamin 3 (Dnm3) in CHIP KO brains. These data 
are consistent with our previous report of increased levels of Dynamin-related protein 1 (Drp1) in CHIP 
KO mice (Lizama et al., 2017) as well as a gene dose-dependent change in Drp1 oxidation (Palubinsky 
et al., 2015). Like Gdap-1, increased Dnm3 and Drp1 should manifest as significant mitochondrial 
fission, but given our analyses these proteins are also unable to drive this process in the absence of 
CHIP.  
CHIP deficiency also resulted in a 2.3-fold increase in the expression of the mitochondrial 
trafficking protein Miro (Rhot1). This Rho GTPase is an outer mitochondrial membrane protein 
involved in regulating mitochondrial morphology and intra- and intercellular trafficking. Miro is 
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essential for ensuring ATP availability for energetically demanding neuronal signaling and 
communication (Tang, 2015). Overexpression of Miro1 or Miro2 increases mitochondrial length 
(Saotome et al., 2008), a finding that is consistent with the elongated phenotype of these organelles in 
CHIP deficient cells. In addition to changing mitochondrial shape, increased Miro expression may be 
causally linked to changes in CHIP expression. Phosphorylation of Miro by PINK1 (Wang et al., 2011b) 
targets the protein for degradation by the E3 ubiquitin ligase Parkin (Liu et al., 2012; Birsa et al., 2014). 
Given the number of overlapping substrates between CHIP and Parkin (Lizama et al., 2017), it is 
possible that CHIP promotes Miro degradation as well. Taken together with increased Gdap-1, Dnm3, 
and Drp1, we suspect that CHIP is a critical link between mitochondrial fission and subsequent 
mitophagy, although more studies are needed to confirm direct protein-protein interactions between 
CHIP and these mitochondrial targets.  
In addition to molecules related to fission-fusion dynamics, we also identified several 
mitochondrial enzymes increased in brains from CHIP KO animals. Alcohol dehydrogenase (ADH), 
also termed s-nitroso glutathione terminase, is elevated 3-fold in CHIP deficient animals. ADH 
eliminates neurotoxic aldehydes generated by lipid peroxidation (O'Brien et al., 2005), consistent with 
our prior report that CHIP deficiency significantly increases CNS F2t-Isoprostanes and Neuroprostanes 
(Palubinsky et al., 2015). These species are derived from the non-enzymatic reduction of the membrane 
lipids arachidonic acid and docosahexaenoic acid. In addition to detoxifying aldehydes, ADH can bind 
A-beta peptide, forming a mitotoxic species that decreases Complex IV activity, oxygen and neural 
glucose utilization and ATP formation, as well as production of ROS (Yao et al., 2011).  
The Krebs cycle enzyme malate dehydrogenase (MDH) is increased 2.2-fold in brains from 
CHIP KO animals. MDH is the final acceptor in the Krebs cycle and is increased in neural cell culture 
models exposed to oxidative stress (Bubber et al., 2005; Shi and Gibson, 2011). The mitochondrial-
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specific isoform, MDH2, interacts with the malate-aspartate shuttle, which facilitates the transfer of 
reducing equivalents from the cytosol to the mitochondria for oxidation (Musrati et al., 1998). 
Pharmacological activators of MDH and the malate-aspartate shuttle are protective in cardiac ischemia-
reperfusion injury models (Stottrup et al., 2010), suggesting that this pathway is rate-limiting and 
increased expression and activity may be part of an effort to adapt to the bioenergetic dysfunction 
caused by chronic loss of CHIP.  
The observed decreases in Glutathione S-Transferase (GST) speak to the intense oxidative stress 
observed in CHIP deficient brain. Glutathione (GSH) is the most abundant cellular antioxidant, and 
maintaining a high ratio of reduced to oxidized glutathione (GSH:GSSG) is essential for cellular health 
(Halliwell and Gutteridge, 1989). GST catalyzes the conjugation of GSH to endogenous and exogenous 
oxidized lipids and proteins for detoxification (Strange et al., 2001). CHIP KO animals have a 4.1-fold 
decrease in GSTA4 expression. This antioxidant is particularly interesting in that it is dually located in 
the cytosol and mitochondria (Raza, 2011; Al Nimer et al., 2013). Within the mitochondria, GSTA4 
detoxifies cells from the lipid peroxidation product 4-hydroxynoneal generated in response to oxidative 
stress (Singhal et al., 2015). The decrease in GSTA4 expression we identified via proteomics 
corroborates our previous findings of increased protein oxidation and lipid peroxidation in CHIP 
deficient animals (Palubinsky et al., 2015). 
Other aspects of cellular protein and lipid oxidation profiles are also clearly impacted by CHIP 
deficiency, including a 2.8-fold decrease in DJ-1 expression. DJ-1 is a redox sensor that functions in 
repairing proteins damaged by glycation during oxidative stress. DJ-1 translocates to mitochondria in 
neural cells after bioenergetic stress and is secreted by injured neurons (Kaneko et al., 2014). Loss of 
DJ-1 increases susceptibility to cell death following acute ischemia-reperfusion in mice (Dongworth et 
al., 2014). As such, novel DJ-1-binding compounds are currently being studied in the context of 
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Parkinson’s disease therapy (Inden et al., 2017) and have the potential to be cross-purposed as 
neuroprotective strategies against acute oxidative stress. These data support a model in which CHIP is a 
critical regulator of redox homeostasis as DJ-1 decreases significantly in its absence, refortifying an 
environment of protein and lipid oxidation. 
Taken together, these data reveal that CHIP expression is critical to mitochondrial quality control 
proteins, bioenergetic enzymes, and redox sensors. These results may explain in part the severe 
abnormalities in mitochondrial shape, cristae structure, and calcium buffering capacity, as well as 
increased neuronal vulnerability to mild bioenergetic stress when CHIP is absent. 
 
	
Table 4 CHIP Loss Changes Expression of Proteins Involved In Mitochondrial Dynamics and 
Energetics. Whole brain lysates from WT and CHIP KO mice (4 male, 4 female for each genotype) were 
analyzed by LC-MS/MS. Proteins listed are >2-fold increased or decreased in KO compared to WT 
based on spectral count data. 
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2.5 Discussion 
The interactions between proteins involved in mitochondrial bioenergetics, redox tone, structure, 
signaling, and autophagy are becoming increasingly well understood, particularly in regards to 
mediating responses to neurological injury and disease. Redox stress sensors like PINK1, DJ-1 and 
apoptosis signaling kinases (ASK) play critical roles in sensing oxidative stress, triggering mitophagy 
and initiating fission and fusion of organelles. The expression and distribution of these proteins are 
regulated by chaperones, protein-protein interactions, redox sensitivity, ubiquitination, and degradation. 
In this work, we show that the chaperone-binding protein, CHIP, is unique among disease-associated 
proteins in that it is both an E3 ligase as well as an essential regulator of mitochondrial number and 
morphology in both physiological and acute pathophysiological stress signaling.  
CHIP was identified as a potential regulator of acute neuronal stress in studies from our lab in 
which we observed increases in CHIP and HSP70 expression that correlate with the time windows of 
neuroprotection observed in ischemic preconditioning (Stankowski et al., 2011). Cells given a low (non-
lethal) level of stress are able to upregulate endogenous protective pathways and withstand any number 
of subsequent injuries including OGD, hypoxia, and oxidative stress (Stetler et al., 2014). We sought to 
evaluate the importance of CHIP using a preconditioning model, as understanding the proteins and 
pathways that control this endogenous form of protection could be leveraged therapeutically. 
Primary neuronal cultures exposed to a short period of oxygen and glucose deprivation proved to 
be a highly effective means to study CHIP redistribution. Here we show that CHIP expression increases 
rapidly in neurons in response to bioenergetic stress, functioning as a critical regulator of 
neuroprotection and mitochondrial autophagic clearance. Within six hours of acute stress, CHIP 
relocalized to mitochondrial membranes. Silencing CHIP expression with siRNA significantly increased 
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neuronal death in response to subsequent stress. These data suggest that CHIP induction, and possibly 
redistribution, are critical events in neurons in order to fend off potentially toxic events. 
We initially hypothesized that when redistributed to the mitochondria, CHIP would promote 
mitophagy in a manner akin to Parkin. Parkin is a well-characterized E3-ubiquitin ligase with similar 
functional domains to CHIP and, based on cell free assays, some redundant client proteins that are 
targeted for degradation (Imai et al., 2002; Kumar et al., 2012). In vitro studies of Parkin revealed its 
roles in mitochondrial quality control and mitophagy (Grunewald et al., 2010; Matsuda et al., 2010; 
Narendra et al., 2010; Rana et al., 2013; Seirafi et al., 2015). CHIP’s ability to compensate for Parkin is 
not unprecedented (Imai et al., 2002), and new studies in Drosophila show that CHIP functions 
downstream of PINK1 signaling, with CHIP overexpression rescuing mitophagy when Parkin is 
deficient (Chen et al., 2017). 
Taken together with biophysical data, it is perhaps not surprising that CHIP is unique among E3 
ligases as it forms asymmetric homodimers with protruding TPR domains. These TPR domains 
transiently bind to the C-terminal domain of HSC/P70. The interfacing Ubox domains then add poly-
ubiquitin chains to exposed K48 residues on client proteins (Scheufler et al., 2000; Schulman and Chen, 
2005; Stankiewicz et al., 2010). Not only does CHIP lack a canonical mitochondrial localization signal, 
but protein relocalization continued to occur even when we introduced mutations that arrest E3 ligase 
function (H260Q) or block HSP70-binding (K30A).  
Surprisingly, mutating these sites enhanced CHIP association with mitochondria after low-level 
bioenergetic stress. One interpretation of this data is that the HSP-bound/ubiquitin ligase functions of 
CHIP are predominantly cytosolic and that the mutations in H260Q or K30A increased a free pool of 
CHIP capable of moving to mitochondria. Another possible interpretation is that HSP70 binding and 
ubiquitin ligase sites are dispensable for relocalization to mitochondria but are needed to drive 
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secondary processes such as mitophagy that would then degrade CHIP/mitochondrial complexes, 
appearing as a decrease in CHIP/mitochondrial association. Indeed, HSC/HSP70 C-terminal CHIP-
binding mutants increase cell vulnerability to stress-induced apoptosis (Mosser et al., 2000), and CHIP 
rescues mitochondrial dysfunction in a Ubox-dependent manner in PINK1 KO drosophila models (Chen 
et al., 2017).  
In the absence of a canonical mitochondrial targeting sequence, our data suggest that the charged 
helix domains of CHIP may mediate mitochondrial localization, or that the TPR and Ubox domains may 
contain unidentified regions that bind with proteins or lipids that facilitate mitochondrial localization. 
Indeed, CHIP was recently shown to bind to lipid membranes enriched in phosphotidylinositol and 
phosphotidic acid, and these lipid substrates compete with chaperones for binding at the TPR domain 
(Kopp et al., 2017). Interestingly, however, Kopp et al. found that purified CHIP protein did not bind 
strongly to cardiolipin using cell-free lipid-binding assays. Cardiolipin, an inner mitochondrial 
membrane lipid, externalizes to the outer mitochondrial membrane in response to mitochondrial injury, 
interacts with LC3, and facilitates mitophagy (Chu et al., 2013). Based on our findings, interrogation of 
CHIP binding with mitochondrial lipids, such as cardiolipin, is warranted using physiological conditions 
and more sensitive detection of lipid-protein interactions, such as subcellular fractionation and mass 
spectrometry. 
We selected the H260Q and K30A mutations based on known functions of CHIP primary 
domains; however, next-generation sequencing of patients with spinocerebellar ataxias has identified 
numerous mutations in the STUB1 gene encoding CHIP protein. In patients with SCAR16, homozygous 
or compound heterozygous point mutations are spread throughout the major structural domains of CHIP, 
resulting in a loss of function (Heimdal et al., 2014; Shi et al., 2014; Synofzik et al., 2014; Bettencourt et 
al., 2015; Kawarai et al., 2016). STUB1 mutations are rare and the clinical phenotype and 
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neuropathological features of these mutations remain poorly described. CHIP likely controls critical 
functions beyond the cerebellum, as patients present not only with progressive limb ataxia, gait 
instability, and cerebellar atrophy but also with dysarthria and mild cognitive impairment (Heimdal et 
al., 2014; Kawarai et al., 2016). 
Genetic mutations in E3 ligases such as X-linked inhibition of apoptosis protein (XIAP), Hrd1, 
and Parkin are associated with Parkinson’s disease and other neurological disorders (Harlin et al., 2001; 
Goldberg et al., 2003; Kaneko et al., 2010). However, recapitulating neuronal death, particularly in 
Parkin knockout mouse models, has largely proven unsuccessful (Perez and Palmiter, 2005). Our data 
suggest that CHIP performs a more vital role in neuronal homeostasis than Parkin. Indeed, CHIP KO 
animals, neurons and MEFs have high baseline levels of oxidative stress, bioenergetic dysfunction and a 
hair-trigger response to injuries that should be non-toxic. Mitochondria are severely deformed with 
swollen cristae and are present in greater numbers when CHIP has been genetically deleted. This 
phenotype is unique compared to observations from other E3 ligase mutants (Stevens et al., 2015; 
Mukherjee and Chakrabarti, 2016; Roy et al., 2016). CHIP deficiency is debilitating, as even 
heterozygous mice have significant motor dysfunction (McLaughlin et al., 2012). Homozygous-null 
mice are too frail to participate in behavioral testing and have significant oxidative dysfunction in the 
CNS and periphery before dying prematurely (Min et al., 2008; McLaughlin et al., 2012; Palubinsky et 
al., 2015). These data stand in stark contrast to Parkin deficient models, which are neurochemically, 
behaviorally and structurally indistinguishable from littermates (Goldberg et al., 2003; Palacino et al., 
2004; Perez and Palmiter, 2005; Lizama et al., 2017).  
The morphological and biochemical changes observed in CHIP deficient mitochondria do, 
however, strikingly parallel mutations in autophagy protein 5 (Atg5) that disrupt formation of the 
Atg12-Atg5 complex. The Atg12-Atg5 conjugate exhibits E3 ligase–like activity, facilitating lipidation 
		73	
of LC3 family members (Otomo et al., 2013). While mice with complete deletion of Atg5 die shortly 
after birth (Yoshii et al., 2016), Atg5 mutations have been identified in patients with ataxia and are 
associated with loss of autophagic signaling in conditional KO models (Kim et al., 2016b). Our data 
support an ‘Atg-5-like’ role for CHIP in normal as well as pathological neuronal mitophagy. As CHIP-
null animals are not embryonic lethal, CHIP deficient mice may also provide a rigorous animal model 
for studying premature aging and susceptibility to neurological injury. 
 
 
 
CHAPTER	3	
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SUMMARY AND FUTURE DIRECTIONS 
 
Summary 
 Since its discovery in 2003, CHIP is now known to be vital for proteostasis, signaling, 
metabolism, and organelle function. This work is the first to reveal the role of CHIP in neuronal 
preconditioning and further supports that contextually- and temporally-regulated mitophagy is 
neuroprotective. However, the complete profile of CHIP activity, particularly with regard to HSP70-
independent or E3 ligase-independent interactions, requires a great deal more study. In this work we 
show that CHIP can be recruited to mitochondria under physiologically-relevant stress, and that this 
localization does not depend on HSP70 binding nor on E3-ligase activity. Within the last year, CHIP has 
been shown to bind PINK1 in a TPR-independent and Ubox-independent manner (Yoo and Chung, 
2018). Additionally, CHIP was shown to bind to plasma membrane lipids in a way that competes with 
HSP70 binding and is dependent upon charged amino acids in the coiled-coil domain (Kopp et al., 
2017). These data support the hypothesis that the unique coiled-coil domain of CHIP may be a yet 
unexplored mechanism for novel protein-protein and protein-lipid interactions.  
 
3.1 CHIP Deficiency As a Model For Pathological Aging and Frailty 
Given the multiple roles of CHIP in cell signaling and survival pathways, it is tempting to 
speculate that non-pathogenic variants of the STUB1 gene render humans that carry these variants 
susceptible to environmental stimuli and toxins. Similar models of gene-environment interactions exist 
for understanding familial and sporadic neurodegenerative diseases, such as Huntington’s disease and 
PD (Cannon and Greenamyre, 2013; Mo et al., 2015). 
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Our group has shown that CHIP haploinsufficient animals (CHIP Het) exhibit motor dysfunction 
beginning at adolescence, despite being able to live as long as their wild-type littermates (McLaughlin et 
al., 2012). Preliminary data comparing WT and CHIP Het adult mice reveal that, despite similar basal 
metabolic rate and activity, CHIP Het animals fail to perform as well on an exercise stress test, reaching 
exhaustion much sooner than their WT littermates.  
These phenotypes strikingly resemble symptoms of frailty, a clinical syndrome affecting more 
than 30% of geriatric adults in the United States (Mohler et al., 2014). Individuals with frailty exhibit a 
progressive physical decline that is defined by five symptoms: weight loss, diminished muscle tone, 
slow walking pace, low physical activity, and exhaustion (Fried et al., 2001). Frailty is associated with 
increased disability, elevated risk of medical co-morbidity, and increased mortality even when 
accounting for common age-associated diseases (Fried et al., 2001; Newman et al., 2001; Woods et al., 
2005; Bandeen-Roche et al., 2006). This syndrome, apart from normal aging, renders individuals highly 
vulnerable to external stressors and leads to poor recovery from injury.  
The causes of frailty remain to be completely elucidated. Thus far, evidence suggests that 
oxidative stress, mitochondrial dysfunction, and chronic inflammation are associated with increased risk 
of frailty. In studies looking at serum from patients, high levels of isoprostanes, oxidized glutathione, 
protein adduction, and DNA damage are associated with frail patients compared to age-matched control 
cohorts (Serviddio et al., 2009; Cesari et al., 2012; Liu et al., 2016). Frail individuals also exhibit lower 
mitochondrial DNA content, which suggests abnormal bioenergetic tone (Ashar et al., 2015).  
Given the increasing geriatric population, mouse models of frailty are a sorely unmet need in 
which to test potential clinical interventions. To date, only two animal models of frailty exist: the 
Interleukin-10 (IL-10) knockout mouse and the Cu/Zn superoxide disumates (Sod1) knockout mouse 
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(Deepa et al., 2017). Like CHIP haploinsufficient animals, IL-10 and Sod1 knockout animals exhibit 
decreased muscle tone, elevated F2t-isoprostanes, and diminished ATP pools (Deepa et al., 2017).  
To assess CHIP deficiency as a mouse model of frailty, future projects characterizing the 
metabolic phenotype of young and aged CHIP haploinsufficent animals are needed. This can be done 
through metabolic and behavioral analyses on adult and geriatric WT and CHIP Het mice in 
collaboration with the Vanderbilt Mouse Metabolic Phenotyping Core. Using the Oxymax system, basal 
activity, oxygen consumption, and fat/lean mass can be monitored over a five-day period. To stress 
animals, exercise endurance tests can be performed while simultaneously recording metabolic rate. We 
suspect that while adult CHIP Het animals will exhibit no differences in basal metabolic rate and 
activity, stressed adult and aged CHIP Het animals will exhibit decreased activity and shifts in metabolic 
tone (i.e. elevated fatty acid metabolism versus oxidative phosphorylation) not observed in WT mice.  
To further elucidate the age-related pathology of CHIP loss, the lipidomic and proteomic profile 
of aged CHIP haploinsufficient animals could be assessed using biochemical and LC/MS techniques, 
identifying biomarkers of frailty and aging in WT and CHIP Het tissues. We suspect that, by comparing 
profiles of young versus aged WT and CHIP Het animals, we will confirm previously recognized 
biomarkers of frailty and identify novel markers of pathological aging. For example, circulating HSP70 
concentrations are correlated with inflammation and frailty in geriatric patients than in an age-matched 
healthy geriatric cohort (Njemini et al., 2011; Ogawa et al., 2012).  
While pathogenic CHIP mutations have been identified in patients with SCA, there remain gaps 
in our understanding of the frequency and phenotype of CHIP heterozygosity or non-SCA-causing 
mutations in CHIP. To understand the frequency of CHIP variants in human populations and 
correlations with frailty and disease risk, we could screen deidentified electronic patient records and 
genomic data provided by the BioVU Synthetic Derivative to determine correlations between SNPs in 
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STUB1, patient frailty, and age-related co-morbidities. We hypothesize that frail patients, as identified 
by standardized frailty assessments, will exhibit biomarkers of frailty that corroborate our CHIP KO and 
Het animal models, as well as exhibit genetic variations in the STUB1 gene.  
 
3.2 CHIP Deficiency As a Model of Aberrant Autophagy 
Autophagic protein and organelle degradation is an essential, highly conserved process that 
regulates normal and pathophysiological processes. The autophagy related proteins (Atgs) were first 
identified and characterized in yeast, but these proteins are conserved across eukaryotes and higher 
vertebrates. The Atgs function in sequential steps in order to orchestrate initiation of membrane 
formation, protein and organelle identification, and engulfment (Reviewed in (Mizushima et al., 2011) 
and (Galluzzi et al., 2017)). Mammalian homologues and functionally redundant proteins in the 
autophagic pathway continue to be identified (Galluzzi et al., 2017).  
Part of the core Atg proteins, Atg5 and Atg12 work cooperatively in the formation of pre-
autophagosomes and function in part as an E3 ligase to facilitate activation of LC3 (Hanada et al., 2007). 
Unsurprisingly, mutants and deletions of Atg5 have been shown to result in profound deficits in 
autophagic signaling, and mice with global deletion of Atg5 die shortly after birth (Hara et al., 2006; 
Yoshii et al., 2016). While autophagy dysfunction is associated with a myriad of diseases (Jiang and 
Mizushima, 2014), mutations in the core non-redundant autophagy proteins have not been reported in 
patients, with the exception of Atg5. Mutations in this gene were recently identified in two patients with 
ataxia with developmental delay (Kim et al., 2016b). This phenotype is consistent with that of patients 
with an early onset, recessive form of spinocerebellar ataxia and mutations in CHIP.  
As discussed in Chapter 1, animals with CHIP deficiency exhibit profound deficits in motor and 
cardiovascular function and premature death, with abnormal mitochondria and autophagic flux 
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(Palubinsky et al., 2015). As described in Chapter 2, we found that in response to acute bioenergetic 
failure, CHIP relocates to mitochondria and colocalizes with the autophagy protein LC3. We are 
interested in continuing comparative analyses of the molecular pathology of CHIP deficiency with that 
of Atg5 deficiency. We seek to determine the ability of Atg5 to compensate for defects in mitophagy 
caused by CHIP deletion and test the hypothesis that Atg5 and CHIP are functional homologues (Figure 
12). 
To determine the susceptibility of CHIP KO and Atg5 KO MEF cells to proteotoxic, energetic, 
and oxidative stress, we could determine how loss of CHIP or loss of Atg5 affects cell viability under 
different stressors. Specifically, we could use acute heat shock to induce proteotoxicity, nutrient 
deprivation to induce energetic stress, and 4-HNE to induce oxidative stress. Using this strategy will 
delineate the protective roles of CHIP and Atg5 in protein triage, mitochondrial quality control, and 
redox homeostasis.  
We have previously shown that CHIP loss leads to abnormal autophagic flux (elevated LC3 and 
p62) in brain tissue (Palubinsky et al., 2015). We suspect that Atg5 is also aberrantly expressed in 
tissues from CHIP deficient animals, particularly in tissues with high metabolic demand, such as the 
brain, heart, and skeletal muscle.  To test this, Atg5 expression and localization will be characterized 
during CHIP deficiency using western blotting and immunofluorescence staining. 
To assess the functional redundancy of CHIP and Atg5 in autophagic flux, we will transfect 
CHIP KO MEFs and primary neurons with an Atg5 overexpression plasmid. Given the rapid 
localization of CHIP to mitochondria during stress and the role of CHIP in maintaining basal energetic 
homeostasis, we hypothesize that, while Atg5 may compensate for defects in autophagy in CHIP KO, 
CHIP is indispensable for mitophagy in the neuronal autophagic pathway. Similarly, we will transfect 
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Atg5 KO MEFs with hCHIP to determine whether CHIP can ameliorate defects in protein and organelle 
turnover.  
	
Figure 12 Hypothesized Role of CHIP and Atg5 in Mitophagy. In normal cells, damaged mitochondria 
are degraded via mitophagy through sequential steps. The kinase PINK1 is stabilized on the OMM of 
damaged mitochondria and phosphorylates OMM proteins and ubiquitin. E3 ligase CHIP is recruited to 
damaged mitochondria and facilitates addition of ubiquitin. Membrane-bound LC3 (LC3-II) is formed 
via the E3 ligase-like activity of the Atg16-Atg5-Atg12 complex and is subsequently recruited to 
damaged organelles for autophagosome formation. There remain significant gaps in knowledge about 
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the lipid and sterol composition of these phagophores, and how these membranes are affected in disease 
states. We hypothesize that CHIP and Atg5 may be functionally redundant. CHIP KO cells accumulate 
sick mitochondria and aggregates of poly-ubiquitinated and oxidized proteins. We suspect that 
overexpession of Atg5 in a CHIP KO system will compensate for loss of CHIP through activation of 
bulk autophagy, consequently improving cell viability. Given that CHIP has lipid membrane binding 
properties in addition to its E3 ligase activity, we suspect that overexpression of CHIP in an Atg5 KO 
system will compensate for the loss of activated LC3 and phagophore fomation. Moreover, we 
hypothesize that CHIP may specifically rescue mitophagy, given that CHIP is recruited to mitochondria 
during stress, to improve cell survival. Red arrows and text indicate hypothesized effects. 
	
3.3 Therapeutic Targets and the Challenges of Reducing CHIP and Parkin-Mediated Pathology 
Opportunities for Targeting E3 Ligases with Off-Label Drugs 
Targeting the UPS has proven successful for the treatment of multiple myeloma and other types 
of cancer (Ghobrial et al., 2016; Guang and Bianchi, 2017). The first FDA approved proteasome 
inhibitor, bortezomib, binds to the 20S proteasome to block the degradation of pro-apoptotic proteins, 
inducing cell cycle arrest (Piperdi et al., 2011; Accardi et al., 2015). Since the approval for use of this 
landmark drug in 2003, several other proteasome inhibitors have been approved or are in late-stage 
clinical trials (Teicher and Tomaszewski, 2015; Manasanch and Orlowski, 2017). Although these drugs 
maintain high specificity and efficacy, proteasome inhibitors are not pathway-specific, targeting the 
latter steps of the UPS during which all protein degradation is affected.  
Upon dissociation from HSP70, Parkin also promotes degradation of the Pael-R receptor during 
times of ER-stress (Imai et al., 2002). This positive regulation of Parkin via the HSP70 chaperone 
complex, as well as an increasing number of disease states in which chaperone machinery and the UPS 
are disrupted (Charan and LaVoie, 2015), again suggests that E3 ligases may be potential therapeutic 
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targets. Further support for E3s as drug targets comes from studies of proteasome inhibition with 
bortezomib (Ruschak et al., 2011) or carfilzomib (Kuhn et al., 2007), which, while effective, were 
shown to result in broad toxicity, off-target effects and increased drug resistance, suggesting that 
enzymes that lie upstream of the proteasome, such as E3 ligases, are a more feasible target (Goldenberg 
et al., 2010; Bulatov and Ciulli, 2015; Huang and Dixit, 2016). Additionally, E3 ligases represent an 
attractive drug target due to the limited number of substrates they target, limiting the regulatory 
pathways affected (Bhowmick et al., 2013; Skaar et al., 2014; Bulatov and Ciulli, 2015; Huang and 
Dixit, 2016). Yet, to date only two inhibitors, Nutlins (Roche) and Lenalidomide (Celgene) for the E3 
ligases MDM2 and CRBN, respectively, have reached clinical trials (Patel and Player, 2008; Skaar et al., 
2014).  
One biochemical feature of RBR E3s that makes them slightly more complex to inhibit 
compared to other E3s is that they require disruption of strong protein-protein interactions, which is 
more difficult than simply targeting a catalytic site (Gonzalez-Ruiz and Gohlke, 2006; Arkin et al., 
2014). A notable biochemical difference of RBR E3 ligases is that they act as scaffolds or adaptors to 
bring the components of the ubiquitination machinery in closer contact with the substrate. In doing so, 
the ubiquitin-conjugated E2 binds to the RING1 domain and then ubiquitin is transferred from the E2 to 
the E3 RING2 domain from which it is then transferred to the substrate (Bielskiene et al., 2015). 
Therefore, inhibiting the activity of RBR E3s requires molecules that interrupt the interaction between 
the ubiquitinated substrate at the substrate interaction domain in order to selectively block degradation 
of a small number of client proteins (Patel and Player, 2008). 
The structure of CHIP makes this protein a more pliable target for small molecule binding. Given 
that the TPR domain is a highly conserved structure, and thousands of TPR proteins have been 
identified, one would suspect that the TPR domain is not a suitably druggable target. Yet, despite a 
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consensus sequence, TPR domain-containing proteins exhibit intra-domain heterogeneity that ultimately 
determines specificity through variation in hydrophobic pockets, residue type and charge, electrostatic 
interaction, and secondary structure flexibility (Zeytuni and Zarivach, 2012). The CHIP TPR domain 
binds weakly to the EEVD motif of HSC/HSP70, which suggests a transient, dynamic function of the 
pro-degradation chaperone complex (Wang et al., 2011a; Smith et al., 2013). Pharmacological 
modulators of the CHIP TPR domain may strengthen or weaken the interaction with the HSC/HSP70 
complex, which may improve proteostasis in a variety of disease contexts. For example, CHIP binding 
to HSP70 is required for recognition of abnormal phospho-tau and will preferentially degrade these 
substrates when HSP90 is pharmacologically inhibited (Dickey et al., 2007b). Given the low-specificity 
and toxicity of most HSP90 inhibitors, combination therapy with modulators of CHIP may be a useful 
strategy (Butler et al., 2015).  
In generating therapeutic strategies for modifying E3 ligase function, it is also important to 
verify which models use naturally-occurring versus synthetic mutants to divulge E3 ligase functions. For 
example, Parkin mutant C431S is not found in patients with PD, but its use in cell culture models 
identified a covalent intermediate in Parkin activation and evidence for its HECT-like activity (Lazarou 
et al., 2013). Additionally, synthetic mutations in CHIP, such as the K30A and H260Q mutations, have 
not been identified in patients but are established tools for delineating the function of CHIP domains (Xu 
et al., 2002).  
 
Controlling Chaperone Activity to Dictate Protein Fate 
Beyond direct control over E3 ligases and their PTM sites, an alternate strategy to change E3 
expression and activity is to change the catalogue of clients presented for ubiquitination and the activity 
of the chaperone complex. Given the role of HSPs in combating a wide variety of cellular stressors, it is 
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not surprising that much research has focused on developing modulators to inhibit or activate these key 
proteins (Holzbeierlein et al., 2010; Neckers and Workman, 2012). The most specific and efficient 
compounds currently available are designed to target the structural components of HSP90, a chaperone 
that responds to a plethora of environmental and physiological stressors (Schopf et al., 2017). 
Investigators initially established HSP90′s ability to be manipulated by drugs such as geldanamycin and 
radicicol. These natural small molecules mimic the ATP-bound structure adopted in the chaperone's N-
terminal nucleotide binding domain (NBD) and cause potent and selective blockade of ATP 
binding/hydrolysis, inhibition of chaperone function, depletion of oncogenic clients, and antitumor 
activity (Neckers and Workman, 2012).  
Chaperone proteins exhibit high levels of structural conservation. For example, eleven members 
of the HSP70 family contain an N-terminal NBD (~40 kDa) and a C-terminal substrate-binding domain 
(SBD) of roughly 25 kDa connected by a short linker (Bertelsen et al., 2009). Similar to HSP90, HSP70 
has unique structural components making it a suitable drug target. Many of the functions of HSP70 
appear to revolve around crosstalk between ATPase activity in the NBD and substrate binding in the 
SBD. HSP70 binds tightly to ATP, and through an allosteric, interdomain interaction, increases the on- 
and off-rate of peptide binding in the adjacent SBD. In turn, nucleotide hydrolysis to ADP closes the 
“lid” and enhances the affinity for substrate. Likewise, interactions between the SBD and its substrates 
increase the rate of ATP hydrolysis in the NBD, suggesting that communication between the two 
domains is two-way (Mayer et al., 2000). From a drug discovery viewpoint, this unique allostery 
provides multiple opportunities for chemical intervention, including inhibition of ATP turnover, 
substrate binding, or even blocking interdomain allostery altogether (Evans et al., 2010).  
The first set of specific allosteric modulators of the HSC70 complex that target the HSP40-
HSC70 interacting or the ATP/ADP substrate binding domains have been developed. Importantly, these 
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regions are conserved across all members of the HSC70 family, including HSP70. The ATP binding 
domain is a critical determinant of chaperone complex activity. When HSC70 family members bind 
HSP40, repetitive cycles of substrate binding and release occur. The affinity of ATP binding, length of 
substrate interaction and strength of substrate affinity therefore determines the fate of the client protein 
by modulating protein refolding or degradation. When bound to the nucleotide site, pro-degradation 
compounds block ATP turnover and drive the complex to release denatured proteins for subsequent 
ubiquitination and degradation. One of these compounds, MKT-077, is being actively explored in 
preclinical and clinical trials as it blocks proliferation of cancer cell lines (Li et al., 2013). On the other 
hand, protein-refolding modulators activate the ATPase domain of HSP40 resulting in the constant 
clamping and release of HSP70-bound substrates required for proper protein refolding (Jinwal et al., 
2009). It is interesting to speculate as to what role CHIP may play when these compounds are 
administered. 
HSPs also indirectly regulate mitochondrial dynamics in mutant models of Parkin. For example, 
expression of DnaJ/Hsp40 chaperone HSJ1a and DNAJB6 was found to rescue mitophagy of 
depolarized mitochondria in cultures expressing a Parkin RING domain mutant (Rose et al., 2011). This 
C289G mutation, found in patients with early-onset autosomal-recessive parkinsonism, causes Parkin to 
aggregate and lose the ability to translocate to mitochondria (Lucking et al., 2000). HSP70 co-
chaperones HSJ1a and DNAJB6 selectively prevented mutated Parkin from forming aggregates (Rose et 
al., 2011). A later study found conflicting data in which expression of these co-chaperones reduced 
aggregated mutant Parkin, but did not rescue mitophagy (Kakkar et al., 2016). The authors attributed 
these conflicting results to the use of different cell lines with differential endogenous Parkin expression. 
Nevertheless, DNAJ proteins were effective in preventing mutant Parkin aggregation in an HSP70-
dependent manner (Kakkar et al., 2016). Therefore, targeting the expression or HSP70-binding capacity 
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of DNAJ co-chaperones may be an additional opportunity for treating PD and other neurodegenerative 
diseases caused by aggregate-prone E3 ligases.  Given the role of CHIP at the mitochondria, similar 
studies investigating the role of CHIP in these models is of intense interest. 
Beyond targeting chaperones themselves, transcription factors that influence the expression of 
chaperones may also be able to regulate E3 function and activity both directly and indirectly. For 
example, under basal physiological conditions, HSF1 is an inactive monomer held in a multiprotein 
complex that includes HSC/HSP70 and HSP90 (Morimoto, 1998). During heat stress, HSF1 undergoes a 
conformational change, trimerizes, and interacts directly with CHIP (Kim et al., 2005). This interaction 
allows HSF1 to localize to the nucleus and induce HSC/HSP70 expression (Dai et al., 2003; Kim et al., 
2005). Thus, perhaps targeting HSF1 by promoting trimerization and subsequent binding with CHIP is a 
promising therapy to upregulate neuroprotective HSP70.  
Activation of HSF1 occurs uniformly in response to treatment with the HSP90 inhibitors 
currently under clinical evaluation. While simultaneously inhibiting the oncogenic Ras/Raf signaling 
pathways, these agents also promote production of soluble and insoluble HSP70 pools (Bagatell et al., 
2000). In neural cells, aggregation of mutant α-synuclein was shown to inhibit HSF1 expression by 
increasing its ubiquitination via the E3 ligase NEDD4 (Kim et al., 2016a). Conversely, introduction of a 
constitutively active form of HSF1 rescues neural cells from α-synuclein-induced toxicity (Liangliang et 
al., 2010). As such, efforts are currently underway to identify and validate modulators of HSF1, HSP70, 
and HSP27 and to explore their functions and validity in combination therapy with HSP90 and other 
chaperone inhibitors.  
CNS drug discovery remains a challenge owing to issues of blood–brain barrier penetrance, first-
pass metabolism, target affinity and selectivity, and therapeutic index (Chico et al., 2009; Abbott, 2013; 
Butlen-Ducuing et al., 2016). The more we uncover about the structure, function and activity of Parkin 
		86	
and CHIP, where known mutations result in devastating disease, the more avenues we open regarding 
how to effectively target and treat neurodegeneration. 
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Appendix A: Design of CHIP Plasmids 
 
Plasmid 1: hCHIP Full Length:mCherry 
Promoter: CHIP Promoter 
ORF1: hCHIP 
Linker: 3xGGGGS 
ORF2: mCherry 
Resistance: Ampicillin 
Promoter Sequence: 
GGGGGCGGGGCCTCTGCTGATGGGGCCGGCGGCTGGGGGCGGGGCCTCTGGATTGGGCGG
CTGCTGGGGGCGGGGCCTCTGCGGATGGGGCCGGCTGCTGGGGGCGGGGCCTCTGGATGG
GGCCGGCTGCCGGGGGAGGGGTCTCTGCGCGTTGGGACAGGGGCGGAACCCCAGGTGGTC
GGGACAGGCTGTTGCGGGAGCGCGCCCTCAGCGAAGCAAGTGAGGCATCTCACTGGGAAA
GTCGAATGTGTGTGGCGGCCGCCGCCGAGGCGGGTTCCGAAGAGACCTCAGCAGGGCAGG
CCAGGGCCTACGCGAACGCCCACCCTTAAGAGCGCGGGGACAGGGAACTGGAGCGTTCCT
CCCAGCCCCCGACGTCGCGGGCCCAGTGTCCCCGTCCAGGCTGGTTGGGCGCACGCGCGGC
CCCACTCGCCCCCACGCGTGCGTCCCCGCTGGTCCCGCCCCCGGCCGGAAGTTCCGGCGGC
GGAGCTGGGCCGGGCCCGAGCGGATCGCGGGCTCGGGCTGCGGGGCTCCGGCTGCGGGCG
CTGGGCCGCGAGGCGCGGAGCTTGGGAGCGGAGCCCAGGCCGTGCCGCGCGGCGCCAT 
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hCHIP:  
ATGAAGGGCAAGGAGGAGAAGGAGGGCGGCGCACGGCTGGGCGCTGGCGGCGGAAGCCC
CGAGAAGAGCCCGAGCGCGCAGGAGCTCAAGGAGCAGGGCAATCGTCTGTTCGTGGGCCG
AAAGTACCCGGAGGCGGCGGCCTGCTACGGCCGCGCGATCACCCGGAACCCGCTGGTGGC
CGTGTATTACACCAACCGGGCCTTGTGCTACCTGAAGATGCAGCAGCACGAGCAGGCCCTG
GCCGACTGCCGGCGCGCCCTGGAGCTGGACGGGCAGTCTGTGAAGGCGCACTTCTTCCTGG
GGCAGTGCCAGCTGGAGATGGAGAGCTATGATGAGGCCATCGCCAATCTGCAGCGAGCTT
ACAGCCTGGCCAAGGAGCAGCGGCTGAACTTCGGGGACGACATCCCCAGCGCTCTTCGAAT
CGCGAAGAAGAAGCGCTGGAACAGCATTGAGGAGCGGCGCATCCACCAGGAGAGCGAGCT
GCACTCCTACCTCTCCAGGCTCATTGCCGCGGAGCGTGAGAGGGAGCTGGAAGAGTGCCAG
CGAAACCACGAGGGTGATGAGGACGACAGCCACGTCCGGGCCCAGCAGGCCTGCATTGAG
GCCAAGCACGACAAGTACATGGCGGACATGGACGAGCTTTTTTCTCAGGTGGATGAGAAG
AGGAAGAAGCGAGACATCCCCGACTACCTGTGTGGCAAGATCAGCTTTGAGCTGATGCGG
GAGCCGTGCATCACGCCCAGTGGCATCACCTACGACCGCAAGGACATCGAGGAGCACCTG
CAGCGTGTGGGTCATTTTGACCCCGTGACCCGGAGCCCCCTGACCCAGGAACAGCTCATCC
CCAACTTGGCTATGAAGGAGGTTATTGACGCATTCATCTCTGAGAATGGCTGGGTGGAGGA
CTACTAA 
 
Linker: 
TCTGGTGGCGGAGGCTCGGGCGGAGGTGGGTCGGGTGGCGGCGGATCA 
 
 
 
		89	
mCherry: 
ATGGTGAGCAAGGGCGAGGAGGATAACATGGCCATCATCAAGGAGTTCATGCGCTTCAAG
GTGCACATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGC
CGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGTGGCCCCCTGCCC
TTCGCCTGGGACATCCTGTCCCCTCAGTTCATGTACGGCTCCAAGGCCTACGTGAAGCACCC
CGCCGACATCCCCGACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTG
ATGAACTTCGAGGACGGCGGCGTGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGC
GAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAACTTCCCCTCCGACGGCCCCGTAATGC
AGAAGAAGACCATGGGCTGGGAGGCCTCCTCCGAGCGGATGTACCCCGAGGACGGCGCCC
TGAAGGGCGAGATCAAGCAGAGGCTGAAGCTGAAGGACGGCGGCCACTACGACGCTGAGG
TCAAGACCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCCCGGCGCCTACAACGTCAACA
TCAAGTTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTACGAACGCGC
CGAGGGCCGCCACTCCACCGGCGGCATGGACGAGCTGTACAAGTAA 
 
Plasmid 2: hCHIP UBox Mutant:mCherry 
Promoter: CHIP Promoter 
ORF1: hCHIP UBox Mutant 
Linker: 3xGGGGS 
ORF2: mCherry 
Resistance: Ampicillin 
Promoter Sequence: 
GGGGGCGGGGCCTCTGCTGATGGGGCCGGCGGCTGGGGGCGGGGCCTCTGGATTGGGCGG
CTGCTGGGGGCGGGGCCTCTGCGGATGGGGCCGGCTGCTGGGGGCGGGGCCTCTGGATGG
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GGCCGGCTGCCGGGGGAGGGGTCTCTGCGCGTTGGGACAGGGGCGGAACCCCAGGTGGTC
GGGACAGGCTGTTGCGGGAGCGCGCCCTCAGCGAAGCAAGTGAGGCATCTCACTGGGAAA
GTCGAATGTGTGTGGCGGCCGCCGCCGAGGCGGGTTCCGAAGAGACCTCAGCAGGGCAGG
CCAGGGCCTACGCGAACGCCCACCCTTAAGAGCGCGGGGACAGGGAACTGGAGCGTTCCT
CCCAGCCCCCGACGTCGCGGGCCCAGTGTCCCCGTCCAGGCTGGTTGGGCGCACGCGCGGC
CCCACTCGCCCCCACGCGTGCGTCCCCGCTGGTCCCGCCCCCGGCCGGAAGTTCCGGCGGC
GGAGCTGGGCCGGGCCCGAGCGGATCGCGGGCTCGGGCTGCGGGGCTCCGGCTGCGGGCG
CTGGGCCGCGAGGCGCGGAGCTTGGGAGCGGAGCCCAGGCCGTGCCGCGCGGCGCCAT 
 
hCHIP UBox Mutant (H260Q) 
ATGAAGGGCAAGGAGGAGAAGGAGGGCGGCGCACGGCTGGGCGCTGGCGGCGGAAGCCC
CGAGAAGAGCCCGAGCGCGCAGGAGCTCAAGGAGCAGGGCAATCGTCTGTTCGTGGGCCG
AAAGTACCCGGAGGCGGCGGCCTGCTACGGCCGCGCGATCACCCGGAACCCGCTGGTGGC
CGTGTATTACACCAACCGGGCCTTGTGCTACCTGAAGATGCAGCAGCACGAGCAGGCCCTG
GCCGACTGCCGGCGCGCCCTGGAGCTGGACGGGCAGTCTGTGAAGGCGCACTTCTTCCTGG
GGCAGTGCCAGCTGGAGATGGAGAGCTATGATGAGGCCATCGCCAATCTGCAGCGAGCTT
ACAGCCTGGCCAAGGAGCAGCGGCTGAACTTCGGGGACGACATCCCCAGCGCTCTTCGAAT
CGCGAAGAAGAAGCGCTGGAACAGCATTGAGGAGCGGCGCATCCACCAGGAGAGCGAGCT
GCACTCCTACCTCTCCAGGCTCATTGCCGCGGAGCGTGAGAGGGAGCTGGAAGAGTGCCAG
CGAAACCACGAGGGTGATGAGGACGACAGCCACGTCCGGGCCCAGCAGGCCTGCATTGAG
GCCAAGCACGACAAGTACATGGCGGACATGGACGAGCTTTTTTCTCAGGTGGATGAGAAG
AGGAAGAAGCGAGACATCCCCGACTACCTGTGTGGCAAGATCAGCTTTGAGCTGATGCGG
GAGCCGTGCATCACGCCCAGTGGCATCACCTACGACCGCAAGGACATCGAGGAGCAACTG
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CAGCGTGTGGGTCATTTTGACCCCGTGACCCGGAGCCCCCTGACCCAGGAACAGCTCATCC
CCAACTTGGCTATGAAGGAGGTTATTGACGCATTCATCTCTGAGAATGGCTGGGTGGAGGA
CTACTGATAA 
 
Linker: 
TCTGGTGGCGGAGGCTCGGGCGGAGGTGGGTCGGGTGGCGGCGGATCA 
 
mCherry: 
ATGGTGAGCAAGGGCGAGGAGGATAACATGGCCATCATCAAGGAGTTCATGCGCTTCAAG
GTGCACATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGC
CGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGTGGCCCCCTGCCC
TTCGCCTGGGACATCCTGTCCCCTCAGTTCATGTACGGCTCCAAGGCCTACGTGAAGCACCC
CGCCGACATCCCCGACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTG
ATGAACTTCGAGGACGGCGGCGTGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGC
GAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAACTTCCCCTCCGACGGCCCCGTAATGC
AGAAGAAGACCATGGGCTGGGAGGCCTCCTCCGAGCGGATGTACCCCGAGGACGGCGCCC
TGAAGGGCGAGATCAAGCAGAGGCTGAAGCTGAAGGACGGCGGCCACTACGACGCTGAGG
TCAAGACCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCCCGGCGCCTACAACGTCAACA
TCAAGTTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTACGAACGCGC
CGAGGGCCGCCACTCCACCGGCGGCATGGACGAGCTGTACAAGTAA 
 
Plasmid 3: hCHIP TPR Mutant:mCherry 
Promoter: CHIP Promoter 
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ORF1: hCHIP TPR Mutant 
Linker: 3xGGGGS 
ORF2: mCherry 
Resistance: Ampicillin 
 
Promoter Sequence: 
GGGGGCGGGGCCTCTGCTGATGGGGCCGGCGGCTGGGGGCGGGGCCTCTGGATTGGGCGG
CTGCTGGGGGCGGGGCCTCTGCGGATGGGGCCGGCTGCTGGGGGCGGGGCCTCTGGATGG
GGCCGGCTGCCGGGGGAGGGGTCTCTGCGCGTTGGGACAGGGGCGGAACCCCAGGTGGTC
GGGACAGGCTGTTGCGGGAGCGCGCCCTCAGCGAAGCAAGTGAGGCATCTCACTGGGAAA
GTCGAATGTGTGTGGCGGCCGCCGCCGAGGCGGGTTCCGAAGAGACCTCAGCAGGGCAGG
CCAGGGCCTACGCGAACGCCCACCCTTAAGAGCGCGGGGACAGGGAACTGGAGCGTTCCT
CCCAGCCCCCGACGTCGCGGGCCCAGTGTCCCCGTCCAGGCTGGTTGGGCGCACGCGCGGC
CCCACTCGCCCCCACGCGTGCGTCCCCGCTGGTCCCGCCCCCGGCCGGAAGTTCCGGCGGC
GGAGCTGGGCCGGGCCCGAGCGGATCGCGGGCTCGGGCTGCGGGGCTCCGGCTGCGGGCG
CTGGGCCGCGAGGCGCGGAGCTTGGGAGCGGAGCCCAGGCCGTGCCGCGCGGCGCCAT 
 
hCHIP TPR Mutant (K30A): 
ATGAAGGGCAAGGAGGAGAAGGAGGGCGGCGCACGGCTGGGCGCTGGCGGCGGAAGCCC
CGAGAAGAGCCCGAGCGCGCAGGAGCTCGCGGAGCAGGGCAATCGTCTGTTCGTGGGCCG
AAAGTACCCGGAGGCGGCGGCCTGCTACGGCCGCGCGATCACCCGGAACCCGCTGGTGGC
CGTGTATTACACCAACCGGGCCTTGTGCTACCTGAAGATGCAGCAGCACGAGCAGGCCCTG
GCCGACTGCCGGCGCGCCCTGGAGCTGGACGGGCAGTCTGTGAAGGCGCACTTCTTCCTGG
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GGCAGTGCCAGCTGGAGATGGAGAGCTATGATGAGGCCATCGCCAATCTGCAGCGAGCTT
ACAGCCTGGCCAAGGAGCAGCGGCTGAACTTCGGGGACGACATCCCCAGCGCTCTTCGAAT
CGCGAAGAAGAAGCGCTGGAACAGCATTGAGGAGCGGCGCATCCACCAGGAGAGCGAGCT
GCACTCCTACCTCTCCAGGCTCATTGCCGCGGAGCGTGAGAGGGAGCTGGAAGAGTGCCAG
CGAAACCACGAGGGTGATGAGGACGACAGCCACGTCCGGGCCCAGCAGGCCTGCATTGAG
GCCAAGCACGACAAGTACATGGCGGACATGGACGAGCTTTTTTCTCAGGTGGATGAGAAG
AGGAAGAAGCGAGACATCCCCGACTACCTGTGTGGCAAGATCAGCTTTGAGCTGATGCGG
GAGCCGTGCATCACGCCCAGTGGCATCACCTACGACCGCAAGGACATCGAGGAGCACCTG
CAGCGTGTGGGTCATTTTGACCCCGTGACCCGGAGCCCCCTGACCCAGGAACAGCTCATCC
CCAACTTGGCTATGAAGGAGGTTATTGACGCATTCATCTCTGAGAATGGCTGGGTGGAGGA
CTACTGATAA 
 
Linker: 
TCTGGTGGCGGAGGCTCGGGCGGAGGTGGGTCGGGTGGCGGCGGATCA 
 
mCherry: 
ATGGTGAGCAAGGGCGAGGAGGATAACATGGCCATCATCAAGGAGTTCATGCGCTTCAAG
GTGCACATGGAGGGCTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGC
CGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGTGGCCCCCTGCCC
TTCGCCTGGGACATCCTGTCCCCTCAGTTCATGTACGGCTCCAAGGCCTACGTGAAGCACCC
CGCCGACATCCCCGACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTG
ATGAACTTCGAGGACGGCGGCGTGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGC
GAGTTCATCTACAAGGTGAAGCTGCGCGGCACCAACTTCCCCTCCGACGGCCCCGTAATGC
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AGAAGAAGACCATGGGCTGGGAGGCCTCCTCCGAGCGGATGTACCCCGAGGACGGCGCCC
TGAAGGGCGAGATCAAGCAGAGGCTGAAGCTGAAGGACGGCGGCCACTACGACGCTGAGG
TCAAGACCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCCCGGCGCCTACAACGTCAACA
TCAAGTTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTACGAACGCGC
CGAGGGCCGCCACTCCACCGGCGGCATGGACGAGCTGTACAAGTA
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